{"content":"<li class=\"n-box-item date-title\" data-end=\"1554263999\" data-start=\"1554177600\" data-txt=\"Monday, December 23, 2019\">Tuesday, April  2, 2019</li><li class=\"n-box-item sa-box-item\" data-id=\"3447941\" data-ts=\"1554246456\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BPI\" target=\"_blank\">BPI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447941-bridgepoint-education-to-change-name-to-zovio-move-to-nasdaq\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bridgepoint Education to change name to Zovio, move to Nasdaq</a></h4><ul><li>Bridgepoint Education (NYSE:<a href='https://seekingalpha.com/symbol/BPI' title='Bridgepoint Education, Inc.'>BPI</a>) <font color=\"green\">+4.1%</font> after-hours on news that the company is <a href=\"https://seekingalpha.com/pr/17464369-zovio-redefine-future-education-technology\" target=\"_blank\">changing its name</a> to Zovio, which it says symbolizes its transformation to an education technology services company.</li><li>The company says it is transferring its listing from the NYSE to the Nasdaq Global Select Market effective April 15, when it will begin trading under the ticker symbol ZVO.</li><li>Zovio also will relocate its headquarters to Chandler, Ariz.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447941\" data-linked=\"Bridgepoint Education to change name to Zovio, move to Nasdaq\" data-tweet=\"$BPI $ZVO - Bridgepoint Education to change name to Zovio, move to Nasdaq https://seekingalpha.com/news/3447941-bridgepoint-education-to-change-name-to-zovio-move-to-nasdaq?source=tweet\" data-url=\"https://seekingalpha.com/news/3447941-bridgepoint-education-to-change-name-to-zovio-move-to-nasdaq\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447931\" data-ts=\"1554241036\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447931-play-gme-and-adxs-among-after-hours-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PLAY, GME and ADXS among after hours movers</a></h4><ul><li><strong>Gainers: </strong><a href='https://seekingalpha.com/symbol/PLAY' title='Dave & Buster&#39;s Entertainment, Inc.'>PLAY</a> <font color=\"green\">+7.6%</font>. <a href='https://seekingalpha.com/symbol/HLIX' title='Helix TCS, Inc.'>OTCQB:HLIX</a> <font color=\"green\">+3.8%</font>. <a href='https://seekingalpha.com/symbol/EVC' title='Entravision Communications Corporation'>EVC</a> <font color=\"green\">+2.8%</font>. <a href='https://seekingalpha.com/symbol/PTGX' title='Protagonist Therapeutics, Inc.'>PTGX</a> <font color=\"green\">+2.3%</font>. <a href='https://seekingalpha.com/symbol/ODT' title='Odonate Therapeutics, Inc.'>ODT</a> <font color=\"green\">+2.1%</font>.</li><li><strong>Losers: </strong><a href='https://seekingalpha.com/symbol/USNA' title='USANA Health Sciences, Inc.'>USNA</a> <font color=\"red\">-15.6%</font>. <a href='https://seekingalpha.com/symbol/ADXS' title='Advaxis, Inc.'>ADXS</a> <font color=\"red\">-14.9%.</font> <a href='https://seekingalpha.com/symbol/GME' title='GameStop Corp.'>GME</a> <font color=\"red\">-7.6%</font>. <a href='https://seekingalpha.com/symbol/MXC' title='Mexco Energy Corporation'>MXC</a> <font color=\"red\">-6.3%. </font><a href='https://seekingalpha.com/symbol/RETA' title='Reata Pharmaceuticals, Inc.'>RETA</a> <font color=\"red\">-2.9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447931\" data-linked=\"PLAY, GME and ADXS among after hours movers\" data-tweet=\"$PLAY $HLIX $EVC - PLAY, GME and ADXS among after hours movers https://seekingalpha.com/news/3447931-play-gme-and-adxs-among-after-hours-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3447931-play-gme-and-adxs-among-after-hours-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:37 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447922\" data-ts=\"1554238979\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447922-altabaplus-2_8-oks-dissolution-plan-estimates-distributions\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Altaba +2.8% as it OKs dissolution plan, estimates distributions</a></h4><ul>   <li>Altaba (NASDAQ:<a href='https://seekingalpha.com/symbol/AABA' title='Altaba, Inc.'>AABA</a>) has received board approval for its <a href=\"https://seekingalpha.com/pr/17464382-altaba-announces-board-approval-plan-complete-liquidation-dissolution\" target=\"_blank\">liquidation and dissolution</a>.</li>    <li>That plan needs stockholder approval, and Altaba will convene a special meeting to secure that.</li>    <li>Shares are <font color=\"green\">up 2.8%</font> after hours.</li>    <li>Altaba has acted generally in order to reduce the discount to net asset value of its shares -- including through repurchases in the open market and an exchange offer for Alibaba ADS (NYSE:<a href='https://seekingalpha.com/symbol/BABA' title='Alibaba Group Holding Limited'>BABA</a>). Altaba is the second-largest shareholder in Alibaba.</li>    <li>\u201cSince June of 2017 we have taken a series of aggressive actions designed to drive shareholder value and these have yielded measurable results as our trading discount has narrowed and our stock has meaningfully outperformed a composite of its underlying assets,\" says CEO Thomas McInerney.</li>    <li>If approved, Altaba would dispose of all its remaining Alibaba stake and equity interest in Excalibur IP; make a pre-dissolution liquidating distribution (which it expects in Q4, for about $52.12-$59.63 in cash and/or Alibaba ADS); and wind up the business.</li>    <li>It's estimating it can make total liquidating distributions (including the pre-dissolution one mentioned above) of $39.8M-$41.1B, about $76.62-$79.22/share. <a href='https://seekingalpha.com/symbol/AABA' title='Altaba, Inc.'>AABA</a> shares closed today at $73.94.</li>    <li><a href='https://seekingalpha.com/symbol/BABA' title='Alibaba Group Holding Limited'>BABA</a> is <font color=\"red\">down 0.7%</font> after hours.</li><li><strong>Updated</strong>: Altaba will hold a <a href=\"http://dpregister.com/10130105\" target=\"_blank\">conference call</a> tomorrow at 8 a.m. ET. At 6:59 p.m., <a href='https://seekingalpha.com/symbol/BABA' title='Alibaba Group Holding Limited'>BABA</a> was <font color=\"red\">down 1.2%</font> postmarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3447922\" data-linked=\"Altaba +2.8% as it OKs dissolution plan, estimates distributions\" data-tweet=\"$AABA $BABA - Altaba +2.8% as it OKs dissolution plan, estimates distributions https://seekingalpha.com/news/3447922-altabaplus-2_8-oks-dissolution-plan-estimates-distributions?source=tweet\" data-url=\"https://seekingalpha.com/news/3447922-altabaplus-2_8-oks-dissolution-plan-estimates-distributions\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>131&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447910\" data-ts=\"1554237148\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GRUB\" target=\"_blank\">GRUB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447910-grubhub-gains-on-new-bull-update\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GrubHub gains on new bull (update)</a></h4><ul><li>BTIG initiates GrubHub (NYSE:<a href='https://seekingalpha.com/symbol/GRUB' title='Grubhub Inc.'>GRUB</a>) at Buy with a $95 PT, implying a 35% upside.</li><li>GRUB is estimated to report earnings on May 7. <a href=\"https://seekingalpha.com/symbol/GRUB/earnings\" target=\"_blank\">Consensus</a> puts revenue at $322.73M with EPS at $0.24.</li><li>GrubHub shares are <font color=\"green\">up 0.9%</font> after hours to $71.21.</li><li>Update with details from the BTIG note:</li><li>Analyst Peter Saleh says GrubHub is well positioned for more restaurant partnerships and predicts \"meaningful\" earnings-per-order growth in the second half of the year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447910\" data-linked=\"GrubHub gains on new bull (update)\" data-tweet=\"$GRUB - GrubHub gains on new bull (update) https://seekingalpha.com/news/3447910-grubhub-gains-on-new-bull-update?source=tweet\" data-url=\"https://seekingalpha.com/news/3447910-grubhub-gains-on-new-bull-update\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447907\" data-ts=\"1554236931\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APRN\" target=\"_blank\">APRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447907-blue-apronplus-4-after-ceo-hiring-and-reaffirming-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Blue Apron +4% after CEO hiring and reaffirming guidance</a></h4><ul> <li>Blue Apron (NYSE:<a href='https://seekingalpha.com/symbol/APRN' title='Blue Apron Holdings, Inc.'>APRN</a>) is <font color=\"green\">up 4.1%</font> in AH trading after <a href=\"https://seekingalpha.com/pr/17464334-blue-apron-appoints-linda-findley-kozlowski-president-chief-executive-officer\" target=\"_blank\">naming</a> Linda Findley Kozlowski as its new CEO.</li> <li>The company says Kozlowski brings a proven record of success at innovative, consumer-focused companies, having most recently served as COO of Etsy.</li> <li>In addition to the C-suite news, Blue Apron reaffirms its prior guidance of a significant improvement in net loss and achieving profitability on an adjusted EBITDA basis in Q1 and for the full year.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3447907\" data-linked=\"Blue Apron +4% after CEO hiring and reaffirming guidance\" data-tweet=\"$APRN - Blue Apron +4% after CEO hiring and reaffirming guidance https://seekingalpha.com/news/3447907-blue-apronplus-4-after-ceo-hiring-and-reaffirming-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3447907-blue-apronplus-4-after-ceo-hiring-and-reaffirming-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447906\" data-ts=\"1554236726\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GME\" target=\"_blank\">GME</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447906-gamestop-slides-to-new-low-after-weak-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GameStop slides to new low after weak outlook</a></h4><ul> <li>GameStop (NYSE:<a href='https://seekingalpha.com/symbol/GME' title='GameStop Corp.'>GME</a>) falls sharply after posting disappointing <a href=\"https://seekingalpha.com/pr/17464288-gamestop-reports-fourth-quarter-fiscal-2018-results-provides-fiscal-2019-outlook\" target=\"_blank\">Q4</a> results and guidance for next year.</li> <li>Consolidated comparable store sales were up 1.4% during the quarter, consisting of a 3.4% increase in the U.S. and 2.9% decrease internationally.</li> <li>New hardware sales fell 9.8% as an increase in Nintendo Switch sales offset by a decline in Xbox One X sales. New software sales were down 7.8%, driven by key titles launching earlier in the year compared to last year. Accessories sales were up 18.8% Y/Y.</li> <li>Gross margin was 24.4% of sales vs. 28.1% consensus and 17.1% a year ago.</li> <li>Looking ahead, GameStop expects Q1 EPS of -$0.05 to $0.00 and both full-year revenue and comp sales growth of -10% to -5%. The comp sales expectation from analysts was around -4%.</li> <li>Shares of GameStop are <font color=\"red\">down 7.08%</font> AH to $9.39 (52-week territory).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3447892-gamestop-beats-0_02-misses-revenue\" target=\"_blank\">GameStop beats by $0.02, misses on revenue</a> (April 2)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3447906\" data-linked=\"GameStop slides to new low after weak outlook\" data-tweet=\"$GME - GameStop slides to new low after weak outlook https://seekingalpha.com/news/3447906-gamestop-slides-to-new-low-after-weak-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3447906-gamestop-slides-to-new-low-after-weak-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>35&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447901\" data-ts=\"1554236276\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADXS\" target=\"_blank\">ADXS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447901-advaxis-readies-equity-offering-shares-down-16\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Advaxis readies equity offering; shares down 16%</a></h4><ul><li>Advaxis (NASDAQ:<a href='https://seekingalpha.com/symbol/ADXS' title='Advaxis, Inc.'>ADXS</a>) is down <font color=\"red\">16%</font> after hours in reaction to its planned <a href=\"https://seekingalpha.com/pr/17464275-advaxis-inc-announces-proposed-public-offering-common-stock\" target=\"_blank\">stock offering</a>. Price, volume and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447901\" data-linked=\"Advaxis readies equity offering; shares down 16%\" data-tweet=\"$ADXS - Advaxis readies equity offering; shares down 16% https://seekingalpha.com/news/3447901-advaxis-readies-equity-offering-shares-down-16?source=tweet\" data-url=\"https://seekingalpha.com/news/3447901-advaxis-readies-equity-offering-shares-down-16\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447896\" data-ts=\"1554236078\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLAY\" target=\"_blank\">PLAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447896-dave-bustersplus-4-after-earnings-topper\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dave &amp; Buster&#39;s +4% after earnings topper</a></h4><ul> <li>Dave &amp; Buster's Entertainment (NASDAQ:<a href='https://seekingalpha.com/symbol/PLAY' title='Dave & Buster&#39;s Entertainment, Inc.'>PLAY</a>) reports comparable sales increased 2.9% in <a href=\"https://seekingalpha.com/pr/17464273-dave-and-buster-s-achieves-q4-comparable-store-sales-increase-2_9-percent\" target=\"_blank\">Q4</a> vs. +2.0% consensus. Comparable store sales increased 4.4% in the amusements/other business and 1.1% in the food &amp; beverage business.</li> <li>Food and Beverage revenue increased 6.5% during the quarter, while amusement/other revenue was up 10.7%.</li> <li>Adjusted EBITDA fell 2.8% to $80.2M during the quarter.</li> <li>Looking ahead, the company sees FY20 revenue of $1.37B to $1.40B vs. $1.38B consensus.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3447890-dave-and-busters-beats-0_11-beats-revenue\" target=\"_blank\">Dave &amp; Buster's beats by $0.11, beats on revenue</a> (April 2)</li><li>PLAY <font color=\"green\">+4.25%</font> AH.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3447896\" data-linked=\"Dave &amp; Buster&#39;s +4% after earnings topper\" data-tweet=\"$PLAY - Dave &amp; Buster&#39;s +4% after earnings topper https://seekingalpha.com/news/3447896-dave-bustersplus-4-after-earnings-topper?source=tweet\" data-url=\"https://seekingalpha.com/news/3447896-dave-bustersplus-4-after-earnings-topper\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447890\" data-ts=\"1554235654\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLAY\" target=\"_blank\">PLAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447890-dave-and-amp-busters-beats-0_11-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dave &amp;amp; Buster&#39;s beats by $0.11, beats on revenue</a></h4><ul><li>Dave &amp; Buster's (NASDAQ:<a href='https://seekingalpha.com/symbol/PLAY' title='Dave & Buster&#39;s Entertainment, Inc.'>PLAY</a>): Q4 GAAP EPS of $0.75 <span style=\"color:green\">beats by $0.11</span>.</li><li>Revenue of $331.78M (+8.8% Y/Y) <font color=\"green\">beats by $6.88M</font>.</li><li>Shares <font color=\"green\">+4.44%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17464273-dave-and-buster-s-achieves-q4-comparable-store-sales-increase-2_9-percent\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3447890\" data-linked=\"Dave &amp;amp; Buster&#39;s beats by $0.11, beats on revenue\" data-tweet=\"$PLAY - Dave &amp; Buster&#39;s beats by $0.11, beats on revenue https://seekingalpha.com/news/3447890-dave-and-amp-busters-beats-0_11-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3447890-dave-and-amp-busters-beats-0_11-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447881\" data-ts=\"1554234378\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPKKY\" target=\"_blank\">SPKKY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447881-hodson-to-take-over-in-spark-new-zealand-ceo-transition\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hodson to take over in Spark New Zealand CEO transition</a></h4><ul>   <li>Spark New Zealand (<a href=\"http://seekingalpha.com/symbol/SPKKY\" target=\"_blank\">SPKKY</a> <font color=\"red\">-2.3%</font>) says its <a href=\"https://www.sparknz.co.nz/news/chief_executive_transition/\" target=\"_blank\">chief executive Simon Moutter has resigned</a>.</li>    <li>Moutter will leave his positions as managing director and as a boardmember on June 30.</li>    <li>The board has appointed Customer Director Jolie Hodson as the new CEO, effective July 1.</li>    <li>The company has been mindful of succession planning as Moutter became managing director in August 2012 with an expected 5-7 year tenure.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3447881\" data-linked=\"Hodson to take over in Spark New Zealand CEO transition\" data-tweet=\"$SPKKY $NZTCF - Hodson to take over in Spark New Zealand CEO transition https://seekingalpha.com/news/3447881-hodson-to-take-over-in-spark-new-zealand-ceo-transition?source=tweet\" data-url=\"https://seekingalpha.com/news/3447881-hodson-to-take-over-in-spark-new-zealand-ceo-transition\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:46 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447880\" data-ts=\"1554234156\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVEO\" target=\"_blank\">AVEO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447880-aveo-up-45-on-new-ficlatuzumab-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aveo up 45% on new ficlatuzumab data</a></h4><ul><li>AVEO Pharmaceuticals (<a href='https://seekingalpha.com/symbol/AVEO' title='AVEO Pharmaceuticals, Inc.'>AVEO</a> <font color=\"green\">+45%</font>) is up on almost a 13x surge in volume on the heels of <a href=\"https://seekingalpha.com/pr/17461981-aveo-biodesix-announce-positive-results-phase-ib-ficlatuzumab-cytarabine-trial-patients\" target=\"_blank\">new data</a> on ficlatuzumab, its hepatocyte growth factor &#40;HGF&#41; inhibitory monoclonal antibody.</li><li>Results from an expansion cohort in a Phase 1b study evaluating the combination of ficlatuzumab and cytarabine in patients with relapsed/refractory acute myeloid leukemia &#40;AML&#41; showed a treatment effect. The data were presented at AACR in Atlanta.</li><li>Out of 11 evaluable patients who received the maximum tolerated dose of ficlatuzumab and cytarabine, six were complete responders (54.5% response rate). The complete response rate in 17 evaluable patients in the study was 52.9% (n=9/17).</li><li>On the safety front, the most frequent serious or life-threatening treatment-related adverse events were febrile neutropenia, abnormal liver enzymes and electrolyte disturbances. There was one death (sepsis) and one case of multi-organ failure that were both disease-related. One patient withdrew due to life-threatening gastrointestinal bleeding which was likely related to ficlatuzumab.</li><li>Shares have almost tripled since March 27 when shares jumped <font color=\"green\">46%</font> on <a href=\"https://seekingalpha.com/news/3446196-aveo-19-percent-m-speculation\" target=\"_blank\">rumors </a>that AstraZeneca was eyeing the company.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447880\" data-linked=\"Aveo up 45% on new ficlatuzumab data\" data-tweet=\"$AVEO - Aveo up 45% on new ficlatuzumab data https://seekingalpha.com/news/3447880-aveo-up-45-on-new-ficlatuzumab-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3447880-aveo-up-45-on-new-ficlatuzumab-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447877\" data-ts=\"1554232765\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447877-microcaps-mostly-among-tech-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Microcaps mostly among tech movers</a></h4><ul><li><strong>Gainers: </strong>Riot Blockchain (NASDAQ:<a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a>) <font color=\"green\">+23%</font>. Phunware (NASDAQ:<a href='https://seekingalpha.com/symbol/PHUN' title='Phunware Inc.'>PHUN</a>) <font color=\"green\">+17%</font>. Technical Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/TCCO' title='Technical Communications Corporation'>TCCO</a>) <font color=\"green\">+16%</font>. SITO Mobile (NASDAQ:<a href='https://seekingalpha.com/symbol/SITO' title='SITO Mobile, Ltd.'>SITO</a>) <font color=\"green\">+13%</font>. Akoustis Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/AKTS' title='Akoustis Technologies, Inc.'>AKTS</a>) <font color=\"green\">+12%</font>.</li> <li><strong>Losers: </strong>Remark Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/MARK' title='Remark Holdings, Inc.'>MARK</a>) <font color=\"red\">-25%</font>. Care.com (NYSE:<a href='https://seekingalpha.com/symbol/CRCM' title='Care.com, Inc.'>CRCM</a>) <font color=\"red\">-11%</font>. Cellcom Israel (NYSE:<a href='https://seekingalpha.com/symbol/CEL' title='Cellcom Israel Ltd.'>CEL</a>) <font color=\"red\">-10%</font>. Nortech Systems Incorporated (NASDAQ:<a href='https://seekingalpha.com/symbol/NSYS' title='Nortech Systems Incorporated'>NSYS</a>) <font color=\"red\">-9%</font>. JMU Limited (NASDAQ:<a href='https://seekingalpha.com/symbol/JMU' title='JMU Limited'>JMU</a>) <font color=\"red\">-9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3447877\" data-linked=\"Microcaps mostly among tech movers\" data-tweet=\"$RIOT $TCCO $SITO - Microcaps mostly among tech movers https://seekingalpha.com/news/3447877-microcaps-mostly-among-tech-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3447877-microcaps-mostly-among-tech-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447875\" data-ts=\"1554232061\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRAY\" target=\"_blank\">CRAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447875-cray-adds-new-intel-processors-to-supercomputers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cray adds new Intel processors to supercomputers</a></h4><ul><li>Cray (<a href='https://seekingalpha.com/symbol/CRAY' title='Cray Inc.'>CRAY</a> <font color='red'>-1.3%</font>) <a href=\"https://seekingalpha.com/pr/17464073-cray-supercomputers-feature-new-intel-xeon-scalable-processors\" target=\"_blank\">reveals</a> it will update its supercomputer product line to include Intel's new Xeon Gold 6200 and Xeon Platinum 8200 processors.</li><li>The processors will be integrated into Cray's CS500 and XC50 supercomputers.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3447868-intel-unveils-cascade-lake-processors\" target=\"_blank\">Intel unveils Cascade Lake processors</a> (April 2)</li></ul><div class=\"tiny-share-widget\" data-id=\"3447875\" data-linked=\"Cray adds new Intel processors to supercomputers\" data-tweet=\"$CRAY - Cray adds new Intel processors to supercomputers https://seekingalpha.com/news/3447875-cray-adds-new-intel-processors-to-supercomputers?source=tweet\" data-url=\"https://seekingalpha.com/news/3447875-cray-adds-new-intel-processors-to-supercomputers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:07 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447865\" data-ts=\"1554229499\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AA\" target=\"_blank\">AA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447865-alcoaminus-2-credit-suisse-cuts-to-neutral\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alcoa -2% as Credit Suisse cuts to Neutral</a></h4><ul><li>Alcoa (<a href='https://seekingalpha.com/symbol/AA' title='Alcoa Corporation'>AA</a> <font color='red'>-2.4%</font>) slides after Credit Suisse <a href=\"https://thefly.com/thestreet/realmoney/index.php/AAid2887308/AA-Alcoa-downgraded-to-Neutral-at-Credit-Suisse\" target=\"_blank\">downgrades</a> shares to Neutral from Outperform with a $31 price target, cut from $40, shifting its valuation framework to focus on \"owned\" EBITDA and free cash  flow on a blended 2019-20 basis to account for the shifting fortunes  between refining and smelting.</li><li>Credit Suisse analyst Curt Woodworth also says China is set to accelerate supply growth over the next several years as capacity swaps convert to new smelters and provincial focus pivots to growth model.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447865\" data-linked=\"Alcoa -2% as Credit Suisse cuts to Neutral\" data-tweet=\"$AA - Alcoa -2% as Credit Suisse cuts to Neutral https://seekingalpha.com/news/3447865-alcoaminus-2-credit-suisse-cuts-to-neutral?source=tweet\" data-url=\"https://seekingalpha.com/news/3447865-alcoaminus-2-credit-suisse-cuts-to-neutral\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:24 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447853\" data-ts=\"1554227959\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447853-gulf-resources-and-emerge-energy-services-among-energy-materials-gainers-mexco-energy-and\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gulf Resources and Emerge Energy Services among Energy/Materials gainers; Mexco Energy and Lilis Energy among losers</a></h4><ul><li><b>Gainers: </b>Gulf Resources (NASDAQ:<a href='https://seekingalpha.com/symbol/GURE' title='Gulf Resources, Inc.'>GURE</a>) <font color=\"green\">+13%</font>. Emerge Energy Services (NYSE:<a href='https://seekingalpha.com/symbol/EMES' title='Emerge Energy Services LP'>EMES</a>) <font color=\"green\">+7%</font>. Key Energy Services (NYSE:<a href='https://seekingalpha.com/symbol/KEG' title='Key Energy Services, Inc.'>KEG</a>) <font color=\"green\">+6%</font>. Sanchez Midstream Partners (NYSEMKT:<a href='https://seekingalpha.com/symbol/SNMP' title='Sanchez Midstream Partners LP'>SNMP</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers: </b>Mexco Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/MXC' title='Mexco Energy Corporation'>MXC</a>) <font color=\"red\">-14%</font>. Lilis Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/LLEX' title='Lilis Energy, Inc.'>LLEX</a>) <font color=\"red\">-9%</font>. Pershing Gold (NASDAQ:<a href='https://seekingalpha.com/symbol/PGLC' title='Pershing Gold Corporation'>PGLC</a>) <font color=\"red\">-8%</font>. SenesTech (NASDAQ:<a href='https://seekingalpha.com/symbol/SNES' title='SenesTech, Inc.'>SNES</a>) <font color=\"red\">-8%</font>. Tengasco (NYSEMKT:<a href='https://seekingalpha.com/symbol/TGC' title='Tengasco, Inc.'>TGC</a>) <font color=\"red\">-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447853\" data-linked=\"Gulf Resources and Emerge Energy Services among Energy/Materials gainers; Mexco Energy and Lilis Energy among losers\" data-tweet=\"$GURE $EMES $KEG - Gulf Resources and Emerge Energy Services among Energy/Materials gainers; Mexco Energy and Lilis Energy among losers https://seekingalpha.com/news/3447853-gulf-resources-and-emerge-energy-services-among-energy-materials-gainers-mexco-energy-and?source=tweet\" data-url=\"https://seekingalpha.com/news/3447853-gulf-resources-and-emerge-energy-services-among-energy-materials-gainers-mexco-energy-and\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:59 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447852\" data-ts=\"1554227720\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JNCE\" target=\"_blank\">JNCE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447852-jounce-up-8-on-new-vopratelimab-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jounce up 8% on new vopratelimab data</a></h4><ul><li>Thinly traded micro cap Jounce Therapeutics (<a href='https://seekingalpha.com/symbol/JNCE' title='Jounce Therapeutics, Inc.'>JNCE</a> <font color=\"green\">+8%</font>) is up on average volume on the heels of <a href=\"https://seekingalpha.com/pr/17464071-jounce-therapeutics-reports-improved-pfs-os-associated-vopratelimab-jtxminus-2011-treatment\" target=\"_blank\">new clinical data</a> on lead candidate vopratelimab (JTX-2011) in patients with solid tumors. The results were presented at AACR in Atlanta.</li><li>Patients in the Phase 1/2 <a href=\"https://clinicaltrials.gov/ct2/show/NCT02904226?titles=iconic&amp;lead=jounce+therapeutics&amp;rank=1\" target=\"_blank\">ICONIC </a>study with ICOS hi CD4 T cells experienced improved progression-free survival &#40;PFS&#41; and overall survival &#40;OS&#41; compared to those with ICOS lo CD4 T cells.</li><li>Specifically, median PFS in the ICOS hi group was 6.2 months compared to 2.0 months for the ICOS lo group. Median OS has not been reached in the ICOS hi cohort versus 9.0 months for ICOS lo.</li><li>Vopratelimab is a monoclonal antibody that binds to and activates a T cell surface protein called ICOS, stimulating an immune response against cancer.</li><li>The company will host an investor and analyst event today at 6:30 pm ET.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447852\" data-linked=\"Jounce up 8% on new vopratelimab data\" data-tweet=\"$JNCE - Jounce up 8% on new vopratelimab data https://seekingalpha.com/news/3447852-jounce-up-8-on-new-vopratelimab-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3447852-jounce-up-8-on-new-vopratelimab-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447850\" data-ts=\"1554227214\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447850-care-comminus-8-best-buy-suspends-relationship\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Care.com -8% as Best Buy suspends relationship</a></h4><ul><li>Best Buy (<a href='https://seekingalpha.com/symbol/BBY' title='Best Buy Co., Inc.'>BBY</a> <font color='red'>-0.7%</font>) <a href=\"https://www.reuters.com/article/us-care-com-best-buy/best-buy-suspends-relationship-with-care-com-idUSKCN1RE1YF?feedType=RSS&amp;feedName=businessNews&amp;utm_source=feedburner&amp;utm_medium=feed&amp;utm_campaign=Feed%3A+reuters%2FbusinessNews+%28Business+News%29\" target=\"_blank\">says </a>it suspended its relationship with Care.com (NYSE:<a href='https://seekingalpha.com/symbol/CRCM' title='Care.com, Inc.'>CRCM</a>) that provided back-up childcare for employees.</li><li>Best Buy spokesman Jeff Shelman says the company is conducting \"a thorough review of both the program and the company.\"</li><li>BTIG <a href=\"https://seekingalpha.com/news/3447539-btig-steps-care-com-sidelines\" target=\"_blank\">mentioned</a> Best Buy's potential exit in its CRCM downgrade yesterday.</li><li>CRCM shares are <font color=\"red\">down 28%</font> in the past month after a Wall Street Journal investigation found problems with the site's listings including improper license identification and owners with criminal backgrounds.</li><li>Care.com is currently <font color=\"red\">down 8.4%</font> to $16.91.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3447414-care-com-minus-7-percent-report-scrubbed-listings\" target=\"_blank\">Care.com -7% on report of scrubbed listings</a> (April 1)</li></ul><div class=\"tiny-share-widget\" data-id=\"3447850\" data-linked=\"Care.com -8% as Best Buy suspends relationship\" data-tweet=\"$BBY $CRCM - Care.com -8% as Best Buy suspends relationship https://seekingalpha.com/news/3447850-care-comminus-8-best-buy-suspends-relationship?source=tweet\" data-url=\"https://seekingalpha.com/news/3447850-care-comminus-8-best-buy-suspends-relationship\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:46 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447849\" data-ts=\"1554227178\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALLY\" target=\"_blank\">ALLY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447849-ally-stock-buyback-surprises-analysts-to-upside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ally stock buyback surprises analysts to the upside</a></h4><ul><li>Ally Financial (<a href='https://seekingalpha.com/symbol/ALLY' title='Ally Financial Inc.'>ALLY</a> <font color='green'>+0.7%</font>)<font color=\"green\"> rose as much as 1.4%</font> on Tuesday after the online bank announced after Wednesday's close a $1.25B stock buyback plan, significantly larger than analysts expected.</li><li>Wells Fargo analyst Donald Fandetti <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/19/04/13469339/analysts-react-to-huge-ally-financial-buyback#/.XKN-A6HuPIs.twitter\" target=\"_blank\">says the buyback</a> plus its 17-cent-per-share dividend puts Ally at slightly higher 100% payout ratio.</li><li>Still, he says the repurchase plan is positive for investors. .</li><li>Morgan Stanley's Betsy Graseck says the buyback was more than twice her estimate of $560M, which was based on expectations for a $1.7B increase in loan loss reserves from a new accounting standard, CECL.</li><li>\"The announcement suggests they think the impact of CECL will be limited, or in any case, lower than the $1.7B we are looking for,\" she wrote.</li><li><a href=\"https://seekingalpha.com/symbol/ALLY/earnings/analyst_ratings\" target=\"_blank\">Analyst ratings</a>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3447483-ally-reports-stock-buyback-1_25b\" target=\"_blank\">Ally reports stock buyback up to $1.25B</a> (April 1)</li></ul><div class=\"tiny-share-widget\" data-id=\"3447849\" data-linked=\"Ally stock buyback surprises analysts to the upside\" data-tweet=\"$ALLY - Ally stock buyback surprises analysts to the upside https://seekingalpha.com/news/3447849-ally-stock-buyback-surprises-analysts-to-upside?source=tweet\" data-url=\"https://seekingalpha.com/news/3447849-ally-stock-buyback-surprises-analysts-to-upside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447845\" data-ts=\"1554226347\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BAND\" target=\"_blank\">BAND</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447845-bandwidthplus-4-on-canaccord-target-boost\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bandwidth +4% on Canaccord target boost</a></h4><ul><li>Canaccord raises its Bandwidth (NASDAQ:<a href='https://seekingalpha.com/symbol/BAND' title='Bandwidth Inc.'>BAND</a>) price target from $60 to $75, matching the Street-high view.</li><li>The firm says BAND \"remains a favorite in small cap\" and sees continuing upside if the company succeeds with international growth, connected home device monetization, or increasing on-network call volumes.</li><li>BAND shares are <font color=\"green\">up 4%</font> to $68.23.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447845\" data-linked=\"Bandwidth +4% on Canaccord target boost\" data-tweet=\"$BAND - Bandwidth +4% on Canaccord target boost https://seekingalpha.com/news/3447845-bandwidthplus-4-on-canaccord-target-boost?source=tweet\" data-url=\"https://seekingalpha.com/news/3447845-bandwidthplus-4-on-canaccord-target-boost\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:32 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447844\" data-ts=\"1554226094\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IQ\" target=\"_blank\">IQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447844-iqiyiminus-2-hsbc-warns-on-advertising-subscriber-pressures\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">IQiyi -2% as HSBC warns on advertising, subscriber pressures</a></h4><ul>   <li>IQiyi (NASDAQ:<a href='https://seekingalpha.com/symbol/IQ' title='iQIYI, Inc.'>IQ</a>) has fallen to a <font color=\"red\">2% decline</font> on the day following a slight price-target trim at HSBC, to a Street low.</li>    <li>The firm has a Hold rating and cut its target by $1/share to $24 on expectations that ad revenue growth was weak in Q1.</li>    <li>That's an issue that could affect other online video or brand advertising platforms, analyst Binnie Wong says, noting also that recent promotions considered key to subscriber growth may have led to sub pricing pressure. (h/t Bloomberg)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3447844\" data-linked=\"IQiyi -2% as HSBC warns on advertising, subscriber pressures\" data-tweet=\"$IQ - IQiyi -2% as HSBC warns on advertising, subscriber pressures https://seekingalpha.com/news/3447844-iqiyiminus-2-hsbc-warns-on-advertising-subscriber-pressures?source=tweet\" data-url=\"https://seekingalpha.com/news/3447844-iqiyiminus-2-hsbc-warns-on-advertising-subscriber-pressures\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447840\" data-ts=\"1554225524\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CVNA\" target=\"_blank\">CVNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447840-carvanaplus-6-after-california-expansion\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Carvana +6% after California expansion</a></h4><ul> <li>Carvana (<a href='https://seekingalpha.com/symbol/CVNA' title='Carvana Co.'>CVNA</a> <font color='green'>+5.7%</font>) rallies after launching in three new California markets.</li><li>The company says it's offer its offering as-soon-as-next-day vehicle delivery to Stockton, Modesto and Vallejo area residents in the state.</li><li>Carvana is now operates in 10 cities in California. The company's as-soon-as-next-day vehicle delivery service is in a total of 112 cities       nationwide.</li>          <li>Source: <a href=\"https://seekingalpha.com/pr/17463256-carvana-brings-new-way-buy-car-three-new-california-markets\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3447840\" data-linked=\"Carvana +6% after California expansion\" data-tweet=\"$CVNA - Carvana +6% after California expansion https://seekingalpha.com/news/3447840-carvanaplus-6-after-california-expansion?source=tweet\" data-url=\"https://seekingalpha.com/news/3447840-carvanaplus-6-after-california-expansion\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447839\" data-ts=\"1554225383\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CVV\" target=\"_blank\">CVV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447839-on-cvd-equipments-q4-results-shares-down-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on CVD Equipment&#39;s Q4 results; shares down 4%</a></h4><ul><li>CVD Equipment (<a href='https://seekingalpha.com/symbol/CVV' title='CVD Equipment Corporation'>CVV</a> <font color=\"red\">-4.2%</font>) reported Q4 revenue decrease of 51.9% Y/Y to $$4.72M.</li><li>MesoScribe from the company\u2019s materials business experienced healthy order growth during the quarter.</li><li>Q4 Gross margin <font color=\"red\">fell by 3,741 bps</font> to 7.6%; and reported operating loss of $1.93M, compared to operating income of $1.78M last year.</li><li>Operating expenses decreased by 13.1% Y/Y to $2.29M.</li><li>Backlog was ~$3M at the year-end, down from year-end 2017. The Company mentioned it has received new orders in excess of $6M in 1Q19.</li><li>Company anticipate revenue in the first two quarters of 2019 may approximate the revenue in the last two quarters of 2018 and therefore the expects to report operating losses in the first two quarters of 2019.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3447457-cvd-equipment-reports-q4-results\" target=\"_blank\">CVD Equipment reports Q4 results</a> (April 1)</li><li><a href=\"https://seekingalpha.com/article/4252213-cvd-equipment-corporation-cvv-ceo-len-rosenbaum-q4-2018-results-earnings-call-transcript\" target=\"_blank\">Transcript</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3447839\" data-linked=\"More on CVD Equipment&#39;s Q4 results; shares down 4%\" data-tweet=\"$CVV - More on CVD Equipment&#39;s Q4 results; shares down 4% https://seekingalpha.com/news/3447839-on-cvd-equipments-q4-results-shares-down-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3447839-on-cvd-equipments-q4-results-shares-down-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447837\" data-ts=\"1554224894\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447837-lexinfintech-holdings-among-financial-gainers-renn-fund-and-siebert-financial-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">LexinFintech Holdings among financial gainers; RENN Fund and Siebert Financial among losers</a></h4><ul><li><b>Gainers:</b> LexinFintech Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/LX' title='LexinFintech Holdings Ltd.'>LX</a>) <font color=\"green\">+8%</font>. China Internet Nationwide Financial Services (NASDAQ:<a href='https://seekingalpha.com/symbol/CIFS' title='China Internet Nationwide Financial Services Inc.'>CIFS</a>) <font color=\"green\">+7%</font>.</li><li><b>Losers:</b> Senior Housing Properties Trust (NASDAQ:<a href='https://seekingalpha.com/symbol/SNH' title='Senior Housing Properties Trust'>SNH</a>) <font color=\"red\">-17%</font>. Medley Management (NYSE:<a href='https://seekingalpha.com/symbol/MDLY' title='Medley Management Inc.'>MDLY</a>) <font color=\"red\">-11%</font>. RENN Fund (NYSEMKT:<a href='https://seekingalpha.com/symbol/RCG' title='RENN Global Entrepreneurs Fund'>RCG</a>) <font color=\"red\">-10%</font>. Siebert Financial (NASDAQ:<a href='https://seekingalpha.com/symbol/SIEB' title='Siebert Financial Corp.'>SIEB</a>) <font color=\"red\">-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447837\" data-linked=\"LexinFintech Holdings among financial gainers; RENN Fund and Siebert Financial among losers\" data-tweet=\"$LX $CIFS $SNH - LexinFintech Holdings among financial gainers; RENN Fund and Siebert Financial among losers https://seekingalpha.com/news/3447837-lexinfintech-holdings-among-financial-gainers-renn-fund-and-siebert-financial-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3447837-lexinfintech-holdings-among-financial-gainers-renn-fund-and-siebert-financial-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:08 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447836\" data-ts=\"1554224586\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447836-biohitech-global-leads-industrial-gainers-concrete-pumping-holdings-in-loser\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BioHiTech Global leads industrial gainers; Concrete Pumping Holdings in loser</a></h4><ul><li><b>Gainers: </b>BioHiTech Global (NASDAQ:<a href='https://seekingalpha.com/symbol/BHTG' title='BioHiTech Global, Inc.'>BHTG</a>) <font color=\"green\">+13%</font>. Euro Tech Holdings Company (NASDAQ:<a href='https://seekingalpha.com/symbol/CLWT' title='Euro Tech Holdings Company Limited'>CLWT</a>) <font color=\"green\">+7%</font>. Kornit Digital (NASDAQ:<a href='https://seekingalpha.com/symbol/KRNT' title='Kornit Digital Ltd.'>KRNT</a>) <font color=\"green\">+5%</font>.</li><li><b>Losers: </b>Concrete Pumping Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/BBCP' title='Concrete Pumping Holdings, Inc.'>BBCP</a>) <font color=\"red\">-18%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447836\" data-linked=\"BioHiTech Global leads industrial gainers; Concrete Pumping Holdings in loser\" data-tweet=\"$BHTG $CLWT $KRNT - BioHiTech Global leads industrial gainers; Concrete Pumping Holdings in loser https://seekingalpha.com/news/3447836-biohitech-global-leads-industrial-gainers-concrete-pumping-holdings-in-loser?source=tweet\" data-url=\"https://seekingalpha.com/news/3447836-biohitech-global-leads-industrial-gainers-concrete-pumping-holdings-in-loser\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:03 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447825\" data-ts=\"1554223146\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTRV\" target=\"_blank\">CTRV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447825-contravir-up-41-on-garlikov-stake\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ContraVir up 41% on Garlikov stake</a></h4><ul><li>Thinly traded nano cap ContraVir Pharmaceuticals (<a href='https://seekingalpha.com/symbol/CTRV' title='ContraVir Pharmaceuticals, Inc.'>CTRV</a> <font color=\"green\">+40.9%</font>) is up on a 9x surge in volume in apparent reaction to a <a href=\"https://www.sec.gov/Archives/edgar/data/1583771/000110465919019188/a19-7406_1sc13g.htm\" target=\"_blank\">13G filed today</a> by Donald Garlikov, the patriarch of a Columbus, OH-based investment management firm, disclosing a 16.6% stake of ~3.4M shares.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447825\" data-linked=\"ContraVir up 41% on Garlikov stake\" data-tweet=\"$CTRV $HEPA - ContraVir up 41% on Garlikov stake https://seekingalpha.com/news/3447825-contravir-up-41-on-garlikov-stake?source=tweet\" data-url=\"https://seekingalpha.com/news/3447825-contravir-up-41-on-garlikov-stake\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:39 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447822\" data-ts=\"1554222908\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447822-healthcare-names-dominate-midday-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare names dominate midday movers</a></h4><ul><li><strong>Gainers: </strong>AVEO Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/AVEO' title='AVEO Pharmaceuticals, Inc.'>AVEO</a>) <font color=\"green\">+35%</font>. ADMA Biologics (NASDAQ:<a href='https://seekingalpha.com/symbol/ADMA' title='ADMA Biologics, Inc.'>ADMA</a>) <font color=\"green\">+32%</font>. Sangamo Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SGMO' title='Sangamo Therapeutics, Inc.'>SGMO</a>) <font color=\"green\">+27%</font>. Castor Maritime (NASDAQ:<a href='https://seekingalpha.com/symbol/CTRM' title='Castor Maritime Inc.'>CTRM</a>) <font color=\"green\">+24%</font>. EDAP TMS S.A. (NASDAQ:<a href='https://seekingalpha.com/symbol/EDAP' title='EDAP TMS S.A.'>EDAP</a>) <font color=\"green\">+23%</font>. Riot Blockchain (NASDAQ:<a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a>) <font color=\"green\">+22%</font>. Vaccinex (NASDAQ:<a href='https://seekingalpha.com/symbol/VCNX' title='Vaccinex, Inc.'>VCNX</a>) <font color=\"green\">+19%</font>. Zynerba Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ZYNE' title='Zynerba Pharmaceuticals, Inc.'>ZYNE</a>) <font color=\"green\">+15%</font>. Safe-T Group (NASDAQ:<a href='https://seekingalpha.com/symbol/SFET' title='Safe-T Group Ltd'>SFET</a>) <font color=\"green\">+13%</font>. Planet Green Holdings (NYSEMKT:<a href='https://seekingalpha.com/symbol/PLAG' title='Planet Green Holdings Corp.'>PLAG</a>) <font color=\"green\">+13%</font>.</li> <li><strong>Losers: </strong>Energy Focus (NASDAQ:<a href='https://seekingalpha.com/symbol/EFOI' title='Energy Focus, Inc.'>EFOI</a>) <font color=\"red\">-49%</font>. Evoke Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/EVOK' title='Evoke Pharma, Inc.'>EVOK</a>) <font color=\"red\">-47%</font>. Apyx Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/APYX' title='Apyx Medical Corporation'>APYX</a>) <font color=\"red\">-47%</font>. Remark Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/MARK' title='Remark Holdings, Inc.'>MARK</a>) <font color=\"red\">-25%</font>. Concrete Pumping Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/BBCP' title='Concrete Pumping Holdings, Inc.'>BBCP</a>) <font color=\"red\">-18%</font>. NovaBay Pharmaceuticals (NYSEMKT:<a href='https://seekingalpha.com/symbol/NBY' title='NovaBay Pharmaceuticals, Inc.'>NBY</a>) <font color=\"red\">-18%</font>. ShiftPixy (NASDAQ:<a href='https://seekingalpha.com/symbol/PIXY' title='ShiftPixy, Inc.'>PIXY</a>) <font color=\"red\">-17%</font>. Senior Housing Properties (NASDAQ:<a href='https://seekingalpha.com/symbol/SNH' title='Senior Housing Properties Trust'>SNH</a>) <font color=\"red\">-16%</font>. NewLink Genetics Corporation (NASDAQ:<a href='https://seekingalpha.com/symbol/NLNK' title='NewLink Genetics Corporation'>NLNK</a>) <font color=\"red\">-15%</font>. Meridian Bioscience (NASDAQ:<a href='https://seekingalpha.com/symbol/VIVO' title='Meridian Bioscience, Inc.'>VIVO</a>) <font color=\"red\">-15%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3447822\" data-linked=\"Healthcare names dominate midday movers\" data-tweet=\"$AVEO $ADMA $SGMO - Healthcare names dominate midday movers https://seekingalpha.com/news/3447822-healthcare-names-dominate-midday-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3447822-healthcare-names-dominate-midday-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:35 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447820\" data-ts=\"1554222587\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CVLT\" target=\"_blank\">CVLT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447820-commvaultminus-6-after-vp-of-sales-resigns\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Commvault -6% after VP of Sales resigns</a></h4><ul><li>CommVault (NASDAQ:<a href='https://seekingalpha.com/symbol/CVLT' title='Commvault Systems, Inc.'>CVLT</a>) shares are <font color=\"red\">down 6.4%</font> after the company <a href=\"https://seekingalpha.com/filing/4428957\" target=\"_blank\">discloses</a> that SVP of worldwide sales Ron Miller resigned this week, effective immediately.</li><li>Miller was with the company for nearly two decades and in the SVP role for eight years.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447820\" data-linked=\"Commvault -6% after VP of Sales resigns\" data-tweet=\"$CVLT - Commvault -6% after VP of Sales resigns https://seekingalpha.com/news/3447820-commvaultminus-6-after-vp-of-sales-resigns?source=tweet\" data-url=\"https://seekingalpha.com/news/3447820-commvaultminus-6-after-vp-of-sales-resigns\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:29 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447821\" data-ts=\"1554222587\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HMC\" target=\"_blank\">HMC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447821-american-honda-sales-rose-4_3-in-march\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">American Honda sales rose 4.3% in March</a></h4><ul><li>Honda (<a href='https://seekingalpha.com/symbol/HMC' title='Honda Motor Co., Ltd.'>HMC</a> <font color='green'>+0.3%</font>) unit sales <a href=\"https://seekingalpha.com/pr/17463895-american-honda-honda-brand-set-march-sales-records-fueled-robust-car-sales-acura-brand\" sasource=\"qp_sum_news_3\" target=\"_blank\">+4.3%</a> to 148,509 units vs. -0.1% forecast by Edmunds.</li><li>Car sales expanded 4.1% and truck sales +4.5%.</li><li>Sales in the Honda division grew 4.1% to 134,101 units, while Acura sales rose 6.4% to 14,408 units, led by 16.6% rise in trucks</li><li>Civic sales increased 3.3% while Accord sales up 5% for the month.</li><li>YTD Honda sales improved 2% to 369,787 units.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447821\" data-linked=\"American Honda sales rose 4.3% in March\" data-tweet=\"$HMC $HNDAF - American Honda sales rose 4.3% in March https://seekingalpha.com/news/3447821-american-honda-sales-rose-4_3-in-march?source=tweet\" data-url=\"https://seekingalpha.com/news/3447821-american-honda-sales-rose-4_3-in-march\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447818\" data-ts=\"1554222391\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DOW\" target=\"_blank\">DOW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447818-new-dowplus-4-in-trading-debut-wins-buy-ratings-from-several-analysts\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New Dow +4% in trading debut, wins Buy ratings from several analysts</a></h4><ul><li>Dow Inc. (<a href='https://seekingalpha.com/symbol/DOW' title='Dow, Inc.'>DOW</a> <font color=\"green\">+4.5%</font>) surges on its <a href=\"https://seekingalpha.com/news/3447600-shares-dow-begin-trade-separation\" target=\"_blank\">first day of trading</a> as an independent chemical company, and the stock is <a href=\"https://www.barrons.com/articles/the-new-dow-stock-is-live-analysts-say-buy-it-now-51554217984\" target=\"_blank\">initiated with positive views</a> at several firms.</li><li>\"Dow offers a <a href=\"https://www.bloomberg.com/news/articles/2019-04-02/dow-inc-jumps-in-first-trading-day-after-split-from-dowdupont\" target=\"_blank\">compelling value opportunity</a>,\" says Goldman's Robert Koort, noting that the shares will pay a \"best-in-class\" dividend yield of ~5.6%; the company's plastics business is approaching a cyclical low set to rebound in 2020, Koort says, as he initiates coverage with a Street-high $71 price target.</li><li>Morgan Stanley analyst Vincent Andrews initiates Dow with an <a href=\"https://thefly.com/thestreet/realmoney/index.php/DOWid2887443/DOW-Dow-Inc-initiated-with-an-Overweight-at-Morgan-Stanley\" target=\"_blank\">Overweight rating</a> and $61 price target, stating that the company has his preferred capital allocation plan for commodity chemical companies: a \"significant return of capital to shareholders, low risk/high reward/short payback period capex, and no large-scale M&amp;A.\"</li><li>BMO Capital's John McNulty <a href=\"https://thefly.com/thestreet/realmoney/index.php/DOWid2887104/DOW-Dow-Inc-initiated-with-an-Outperform-at-BMO-Capital\" target=\"_blank\">starts Dow at Outperform</a> with a $64 price target, seeing a \"compelling\" risk/reward profile despite a \"tough\" macro environment and saying management's focus on returns, capital discipline and return of  cash to shareholders \"should better serve investors in the future.\"</li><li>BofA/Merrill's Steve Byrne <a href=\"https://thefly.com/thestreet/realmoney/index.php/DOWid2887481/DOW-Dow-Inc-initiated-with-a-Buy-at-BofAMerrill\" target=\"_blank\">initiates Dow with a Buy</a> and $64 price target, citing under-appreciated profitability potential, productivity improvements and cross-business collaboration initiatives.</li><li>Meanwhile, DowDuPont (<a href='https://seekingalpha.com/symbol/DWDP' title='DowDuPont Inc.'>DWDP</a> <font color=\"green\">+0.1%</font>) shows little change after the spinoff; Citi's P.J. Juvekar downgrades shares to Neutral from Buy with a $40 price target, cut from $60, saying his estimated total return of 10% does not  justify a Buy rating.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447818\" data-linked=\"New Dow +4% in trading debut, wins Buy ratings from several analysts\" data-tweet=\"$DOW $DWDP $DOW - New Dow +4% in trading debut, wins Buy ratings from several analysts https://seekingalpha.com/news/3447818-new-dowplus-4-in-trading-debut-wins-buy-ratings-from-several-analysts?source=tweet\" data-url=\"https://seekingalpha.com/news/3447818-new-dowplus-4-in-trading-debut-wins-buy-ratings-from-several-analysts\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:26 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>33&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447814\" data-ts=\"1554222166\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EFOI\" target=\"_blank\">EFOI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447814-energy-focus-tumbles-50-post-q4-results-miss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy Focus tumbles 50% post Q4 results miss</a></h4><div><ul><li>Energy Focus (<a href='https://seekingalpha.com/symbol/EFOI' title='Energy Focus, Inc.'>EFOI</a> <font color=\"red\">-50.4%</font>) reported Q4 revenue decrease of 34% Y/Y to $3.12M. Segment Sales: Commercial products sales were $1.2M (-60.4% Y/Y), declines were due to unexpected budgetary delays, push outs in retrofit project starts and losses to lower priced competitors; and Military and maritime products sales were $1.9M (+12.4% Y/Y).</li><li>Q4 Gross margin <font color=\"red\">fell by 3,370 bps</font> to 0.61%; Loss from operations expanded to $2.97M, compared to $1.88M a year ago; and Adj. EBITDA loss expanded to $2.48M, compared to $1.26M last year.</li><li>Net cash used in operating activities for the quarter were $2.95M, compared to $1.19M a year ago.</li><li>Company has Cash and cash equivalents of $6.34M, as of December 31, 2018.</li><li>Energy Focus announced that, following a process to evaluate its strategic options, it has completed a strategic financing, which includes changes to its Board of Directors.</li><li>The strategic financing provided company with about $1.7M in exchange for subordinated convertible promissory notes. In connection with the financing, the Board of Directors appointed James Tu and Robert Farkas to join the Board, effective following the filing of Annual Report on Form 10-K.</li><li>Mr. Tu will also return to the position of Chairman, CEO and President and serve as its interim CFO effective April 2, 2019.</li><li>The Company\u2019s initial actions included the elimination of 12 positions, restructuring of the sales organization and incentive plan, flattening of the senior management team, additional operational streamlining, management compensation reductions, and outsourcing of certain functions including warehousing and marketing.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3447520-energy-focus-misses-0_10-misses-revenue\" target=\"_blank\">Energy Focus misses by $0.10, misses on revenue</a> (April 1)</li></ul></div><div class=\"tiny-share-widget\" data-id=\"3447814\" data-linked=\"Energy Focus tumbles 50% post Q4 results miss\" data-tweet=\"$EFOI - Energy Focus tumbles 50% post Q4 results miss https://seekingalpha.com/news/3447814-energy-focus-tumbles-50-post-q4-results-miss?source=tweet\" data-url=\"https://seekingalpha.com/news/3447814-energy-focus-tumbles-50-post-q4-results-miss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:22 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447811\" data-ts=\"1554220940\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447811-sunopta-and-fuwei-films-among-consumer-gainers-vuzix-and-eastman-kodak-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SunOpta and Fuwei Films among consumer gainers; Vuzix and Eastman Kodak among losers</a></h4><ul><li><b>Gainers: </b>Planet Green Holdings (NYSEMKT:<a href='https://seekingalpha.com/symbol/PLAG' title='Planet Green Holdings Corp.'>PLAG</a>) <font color=\"green\">+13%</font>. SunOpta (NASDAQ:<a href='https://seekingalpha.com/symbol/STKL' title='SunOpta Inc.'>STKL</a>) <font color=\"green\">+10%</font>. Fuwei Films (NASDAQ:<a href='https://seekingalpha.com/symbol/FFHL' title='Fuwei Films &#40;Holdings&#41; Co., Ltd.'>FFHL</a>) <font color=\"green\">+8%</font>. Acme United (NYSEMKT:<a href='https://seekingalpha.com/symbol/ACU' title='Acme United Corporation'>ACU</a>) <font color=\"green\">+6%</font>. The Lovesac Company (NASDAQ:<a href='https://seekingalpha.com/symbol/LOVE' title='The Lovesac Company'>LOVE</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers: </b>Energy Focus (NASDAQ:<a href='https://seekingalpha.com/symbol/EFOI' title='Energy Focus, Inc.'>EFOI</a>) <font color=\"red\">-52%</font>. Amira Nature Foods (NYSE:<a href='https://seekingalpha.com/symbol/ANFI' title='Amira Nature Foods Ltd.'>ANFI</a>) <font color=\"red\">-13%</font>. Vuzix (NASDAQ:<a href='https://seekingalpha.com/symbol/VUZI' title='Vuzix Corporation'>VUZI</a>) <font color=\"red\">-12%</font>. Eastman Kodak (NYSE:<a href='https://seekingalpha.com/symbol/KODK' title='Eastman Kodak Company'>KODK</a>) <font color=\"red\">-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447811\" data-linked=\"SunOpta and Fuwei Films among consumer gainers; Vuzix and Eastman Kodak among losers\" data-tweet=\"$PLAG $STKL $FFHL - SunOpta and Fuwei Films among consumer gainers; Vuzix and Eastman Kodak among losers https://seekingalpha.com/news/3447811-sunopta-and-fuwei-films-among-consumer-gainers-vuzix-and-eastman-kodak-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3447811-sunopta-and-fuwei-films-among-consumer-gainers-vuzix-and-eastman-kodak-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447806\" data-ts=\"1554220177\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447806-intelsat-higher-after-ctia-spectrum-report-buyer-chatter\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intelsat higher after CTIA spectrum report, buyer chatter</a></h4><ul>   <li>Intelsat (NYSE:<a href='https://seekingalpha.com/symbol/I' title='Intelsat S.A.'>I</a>) is <font color=\"green\">up 2%</font> and jumped to a two-week high today after a report from wireless trade group CTIA that supported a free-market approach to spectrum policy.</li>    <li>The group urged harnessing \"the power of competition\" in dealing with airwaves, in part to secure economic and national security.</li>    <li>It's also pushing a five-year schedule of airwaves auctions along with modernizing policy.</li>    <li>Meanwhile, Bloomberg notes trader rumors that AT&amp;T (NYSE:<a href='https://seekingalpha.com/symbol/T' title='AT&T Inc.'>T</a>) may be interested in Intelsat spectrum.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3447806\" data-linked=\"Intelsat higher after CTIA spectrum report, buyer chatter\" data-tweet=\"$I $T - Intelsat higher after CTIA spectrum report, buyer chatter https://seekingalpha.com/news/3447806-intelsat-higher-after-ctia-spectrum-report-buyer-chatter?source=tweet\" data-url=\"https://seekingalpha.com/news/3447806-intelsat-higher-after-ctia-spectrum-report-buyer-chatter\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447804\" data-ts=\"1554220015\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BHTG\" target=\"_blank\">BHTG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447804-biohitech-global-rallies-11_2-post-fy-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BioHiTech Global rallies 11.2% post FY results</a></h4><ul><li>BioHiTech Global (<a href='https://seekingalpha.com/symbol/BHTG' title='BioHiTech Global, Inc.'>BHTG</a> <font color=\"green\">+11.2%</font>) reported <a href=\"https://seekingalpha.com/pr/17462008-biohitech-global-reports-full-year-2018-results\" target=\"_blank\">FY</a> revenue growth of 38.8% Y/Y to $3.36M.</li><li>The company received $3.5M in cash and $2M in assets from Kinderhook Industries backed Gold Medal Group into subsidiary to advance planned US HEBioT facility roll-out strategy.</li><li>Recurring revenue derived from rental, service and maintenance increased 11.1% Y/Y to $1.8M;</li><li>Gross margin rose by <font color=\"green\">2,080 bps</font> to 51.2% &amp; rental, service and maintenance gross margin <font color=\"green\">increased by 570 bps</font> to 31.3%.</li><li>The total number of units under lease contract grew by 86.8% to 170 units, reflecting the successful deployment of less expensive Revolution Series Digesters.</li><li>The company completed the uplisting of its common stock to The Nasdaq Capital Market in the Q2 2018.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3447461-biohitech-global-misses-revenue\" target=\"_blank\">BioHiTech Global misses on revenue</a> (Apr. 01 2019)</li></ul><div class=\"tiny-share-widget\" data-id=\"3447804\" data-linked=\"BioHiTech Global rallies 11.2% post FY results\" data-tweet=\"$BHTG - BioHiTech Global rallies 11.2% post FY results https://seekingalpha.com/news/3447804-biohitech-global-rallies-11_2-post-fy-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3447804-biohitech-global-rallies-11_2-post-fy-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:46 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447795\" data-ts=\"1554218401\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WYNN\" target=\"_blank\">WYNN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447795-wynn-resortsplus-2-after-ma-gaming-commission-report-filed\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wynn Resorts +2% after MA Gaming Commission report filed</a></h4><ul> <li>The Massachusetts Gaming Commission has issued a <a href=\"https://www.wsj.com/edition/resources/documents/print/A.%20FINAL%20REPORT%20-%20FINAL%20REDACTED%20VERSION%203.29.19.pdf\" target=\"_blank\">199-page report</a> on Wynn Resorts (NASDAQ:<a href='https://seekingalpha.com/symbol/WYNN' title='Wynn Resorts, Limited'>WYNN</a>) regarding the suitability of the company in regard to its application for a gaming license in the state.</li> <li>The report arrived just in front of three days of commission hearings in Boston on the issue.</li> <li>The report indicates that the investigation determined Wynn execs and outside counsel attempted to protect Steve Wynn as a part of a coverup, including not following policies and procedures when allegations were filed of sexual misconduct.</li> <li>The commission is advised to evaluate Wynn's \"remedial measures\" in light of the evidence provided in the report.</li><li>Shares of Wynn are <font color=\"green\">up 1.99%</font> on the day, with many of the report findings anticipated or already known by investors and analysts.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3447626-union-gaming-expects-win-wynn-massachusetts\" target=\"_blank\">Union Gaming expects a win for Wynn in Massachusetts</a> (April 2)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3447795\" data-linked=\"Wynn Resorts +2% after MA Gaming Commission report filed\" data-tweet=\"$WYNN - Wynn Resorts +2% after MA Gaming Commission report filed https://seekingalpha.com/news/3447795-wynn-resortsplus-2-after-ma-gaming-commission-report-filed?source=tweet\" data-url=\"https://seekingalpha.com/news/3447795-wynn-resortsplus-2-after-ma-gaming-commission-report-filed\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447789\" data-ts=\"1554217939\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRIL\" target=\"_blank\">TRIL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447789-trillium-adds-sting-candidate-to-pipeline\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trillium adds STING candidate to pipeline</a></h4><ul><li>Trillium Therapeutics (<a href='https://seekingalpha.com/symbol/TRIL' title='Trillium Therapeutics Inc.'>TRIL</a> <font color=\"red\">-4.4%</font>) has <a href=\"https://seekingalpha.com/pr/17462683-trillium-therapeutics-expands-immuno-oncology-pipeline-sting-agonist-program\" target=\"_blank\">added </a>a STING (stimulator of interferon genes) agonist program to its pipeline named TTI-10001, a development that apparently lacks investor enthusiasm.</li><li><a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5004891/\" target=\"_blank\">STING </a>is a signaling protein involved in sensing DNA in the liquid inside a cell (cytosolic) that plays a key role in promoting tumor immunity.</li><li>The company says its candidate is different from others considering its small molecule characteristics, including favorable potency, cell permeability and enhanced tumor retention, adding that other candidates are based on high molecular weight molecules called cyclic dinucleotides that have undesirable properties.</li><li>Preclinical data presented at AACR in Atlanta showed that intratumoral administration of TTI-10001 induced complete regression in both injected and distal tumors in mouse models.</li><li>STING-related tickers: Merck (<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co., Inc.'>MRK</a> <font color=\"red\">-0.1%</font>); Bristol-Myers Squibb (<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a> <font color=\"red\">-0.2%</font>); Aduro Biotech (<a href='https://seekingalpha.com/symbol/ADRO' title='Aduro BioTech, Inc.'>ADRO</a> <font color=\"green\">+2%</font>); Novartis (<a href='https://seekingalpha.com/symbol/NVS' title='Novartis AG'>NVS</a> <font color=\"red\">-0.8%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3447789\" data-linked=\"Trillium adds STING candidate to pipeline\" data-tweet=\"$TRIL $MRK $BMY - Trillium adds STING candidate to pipeline https://seekingalpha.com/news/3447789-trillium-adds-sting-candidate-to-pipeline?source=tweet\" data-url=\"https://seekingalpha.com/news/3447789-trillium-adds-sting-candidate-to-pipeline\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:12 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447790\" data-ts=\"1554217534\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447790-sangamo-therapeutics-and-aveo-pharmaceuticals-among-healthcare-gainers-advaxis-and-evoke\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sangamo Therapeutics and AVEO Pharmaceuticals among healthcare gainers; Advaxis and Evoke Pharma among losers</a></h4><ul><li><b>Gainers: </b>ADMA Biologics (NASDAQ:<a href='https://seekingalpha.com/symbol/ADMA' title='ADMA Biologics, Inc.'>ADMA</a>) <font color=\"green\">+36%</font>. Sangamo Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SGMO' title='Sangamo Therapeutics, Inc.'>SGMO</a>) <font color=\"green\">+31%</font>. AVEO Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/AVEO' title='AVEO Pharmaceuticals, Inc.'>AVEO</a>) <font color=\"green\">+31%</font>. EDAP TMS (NASDAQ:<a href='https://seekingalpha.com/symbol/EDAP' title='EDAP TMS S.A.'>EDAP</a>) <font color=\"green\">+23%</font>. Ovid Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/OVID' title='Ovid Therapeutics Inc.'>OVID</a>) <font color=\"green\">+13%</font>.</li><li><b>Losers: </b>Evoke Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/EVOK' title='Evoke Pharma, Inc.'>EVOK</a>) <font color=\"red\">-47%</font>. Apyx Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/APYX' title='Apyx Medical Corporation'>APYX</a>) <font color=\"red\">-47%</font>. NovaBay Pharmaceuticals (NYSEMKT:<a href='https://seekingalpha.com/symbol/NBY' title='NovaBay Pharmaceuticals, Inc.'>NBY</a>) <font color=\"red\">-30%</font>. Meridian Bioscience (NASDAQ:<a href='https://seekingalpha.com/symbol/VIVO' title='Meridian Bioscience, Inc.'>VIVO</a>) <font color=\"red\">-17%</font>. Advaxis (NASDAQ:<a href='https://seekingalpha.com/symbol/ADXS' title='Advaxis, Inc.'>ADXS</a>) <font color=\"red\">-12%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447790\" data-linked=\"Sangamo Therapeutics and AVEO Pharmaceuticals among healthcare gainers; Advaxis and Evoke Pharma among losers\" data-tweet=\"$ADMA $SGMO $AVEO - Sangamo Therapeutics and AVEO Pharmaceuticals among healthcare gainers; Advaxis and Evoke Pharma among losers https://seekingalpha.com/news/3447790-sangamo-therapeutics-and-aveo-pharmaceuticals-among-healthcare-gainers-advaxis-and-evoke?source=tweet\" data-url=\"https://seekingalpha.com/news/3447790-sangamo-therapeutics-and-aveo-pharmaceuticals-among-healthcare-gainers-advaxis-and-evoke\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:05 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447788\" data-ts=\"1554217331\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FSUMF\" target=\"_blank\">FSUMF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447788-fortescue-metals-oks-development-of-2_6b-australian-iron-ore-project\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fortescue Metals OKs development of $2.6B Australian iron ore project</a></h4><ul><li>Fortescue Metals (<a href='https://seekingalpha.com/symbol/FSUMF' title='Fortescue Metals Group Limited'>OTCQX:FSUMF</a> <font color='green'>+1.7%</font>) and Taiwanese partner Formosa Steel say they will <a href=\"https://www.afr.com/business/mining/fortescue-metals-to-develop-3-7b-mine-20190402-p519uv\" target=\"_blank\">move forward with development</a> of the Iron Bridge magnetite iron ore project in Western Australia, with plans to spend $2.6B (A$3.7B)  to substantially boost the grade of its iron ore exports.</li><li>Fortescue expects the project to produce 22M mt/year of 67% iron ore magnetite concentrate when it is running at full operational capacity, with delivery of first ore anticipated in H1 2022.</li><li>The Iron Bridge approval follows Fortescue's decision less than a year ago to build the $1.2B Eliwana hematite iron ore mine due to begin production in late 2020.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447788\" data-linked=\"Fortescue Metals OKs development of $2.6B Australian iron ore project\" data-tweet=\"$FSUMF - Fortescue Metals OKs development of $2.6B Australian iron ore project https://seekingalpha.com/news/3447788-fortescue-metals-oks-development-of-2_6b-australian-iron-ore-project?source=tweet\" data-url=\"https://seekingalpha.com/news/3447788-fortescue-metals-oks-development-of-2_6b-australian-iron-ore-project\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:02 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447785\" data-ts=\"1554217312\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ANFI\" target=\"_blank\">ANFI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447785-amira-nature-foodsminus-15-after-sales-update\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amira Nature Foods -15% after sales update</a></h4><ul> <li>Amira Nature Foods (NYSE:<a href='https://seekingalpha.com/symbol/ANFI' title='Amira Nature Foods Ltd.'>ANFI</a>) <font color=\"red\">falls 15.3%</font> after updating on six-month results for the period ending last September 30. The company reported a revenue tally of $123.7M for the period.</li> <li>The company is not providing guidance for the remaining half of the fiscal year that ended on March 31, due in part to Amira's capital constraints and the financial climate in India.</li> <li>Shares of ANFI have doubled since the start of the year after a freefall during the back half of last year.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3447504-amira-nature-foods-announces-revenue-six-months-ended-september-30\" target=\"_blank\">Amira Nature Foods announces revenue for six months ended September 30</a> (April 1)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3447785\" data-linked=\"Amira Nature Foods -15% after sales update\" data-tweet=\"$ANFI - Amira Nature Foods -15% after sales update https://seekingalpha.com/news/3447785-amira-nature-foodsminus-15-after-sales-update?source=tweet\" data-url=\"https://seekingalpha.com/news/3447785-amira-nature-foodsminus-15-after-sales-update\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447777\" data-ts=\"1554216635\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IDXG\" target=\"_blank\">IDXG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447777-interpace-up-1-on-new-test-coverage\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Interpace up 1% on new test coverage</a></h4><ul><li>Interpace Diagnostics (<a href='https://seekingalpha.com/symbol/IDXG' title='Interpace Diagnostics Group, Inc.'>IDXG</a>) is up <font color=\"green\">1%</font> on below-average volume in response to its <a href=\"https://seekingalpha.com/pr/17462597-interpace-diagnostics-announces-new-coverage-thyroid-testing-medica\" target=\"_blank\">announcement </a>that Medica, a Midwest-concentrated health insurer protecting 1.3M lives, is now covering the ThyGeNEXT and ThyraMIR tests.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447777\" data-linked=\"Interpace up 1% on new test coverage\" data-tweet=\"$IDXG - Interpace up 1% on new test coverage https://seekingalpha.com/news/3447777-interpace-up-1-on-new-test-coverage?source=tweet\" data-url=\"https://seekingalpha.com/news/3447777-interpace-up-1-on-new-test-coverage\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:50 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447781\" data-ts=\"1554216473\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TDY\" target=\"_blank\">TDY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447781-cowen-bullish-on-teledynes-fcf-potential\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cowen bullish on Teledyne&#39;s FCF potential</a></h4><ul><li>Cowen intiates Teledyne (NYSE:<a href='https://seekingalpha.com/symbol/TDY' title='Teledyne Technologies Incorporated'>TDY</a>) with an Outperform rating and Street-high $265 price target citing the potential to generate organic FCF of nearly $2.5B over the next five years.</li><li>The firm says TDY has a \"uniquely curated, diverse portfolio with secular leverage to high-end vision technologies, precision instrumentation, and modern warfare.\"</li><li>TDY shares are <font color=\"green\">up 0.4%</font> to $241.10.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447781\" data-linked=\"Cowen bullish on Teledyne&#39;s FCF potential\" data-tweet=\"$TDY - Cowen bullish on Teledyne&#39;s FCF potential https://seekingalpha.com/news/3447781-cowen-bullish-on-teledynes-fcf-potential?source=tweet\" data-url=\"https://seekingalpha.com/news/3447781-cowen-bullish-on-teledynes-fcf-potential\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447766\" data-ts=\"1554215393\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IDRA\" target=\"_blank\">IDRA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447766-idera-up-8-on-early-stage-tilsotolimod-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Idera up 8% on early-stage tilsotolimod data</a></h4><ul><li>Thinly traded nano cap Idera Pharmaceuticals (<a href='https://seekingalpha.com/symbol/IDRA' title='Idera Pharmaceuticals, Inc.'>IDRA</a> <font color=\"green\">+7.7%</font>) is up on average volume on the heels of <a href=\"https://seekingalpha.com/pr/17462670-idera-pharmaceuticals-presents-illuminateminus-101-data-demonstrating-tilsotolimod-activates\" target=\"_blank\">data </a>from a Phase 1 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03052205?term=illuminate-101&amp;rank=1\" target=\"_blank\">ILLUMINATE-101</a>, evaluating tilsotolimod in patients with treatment-resistant solid tumors. The results are being presented today at AACR in Atlanta.</li><li>The disease control rate (responders + stable cancer) was 44.8% (n=13/29), but there were no responders. Five of the 13 experienced maximum tumor shrinkage greater than 10% from baseline. Duration of stable cancer ranged from 1.3 months to 9.7+ months with three ongoing.</li><li>No correlations were observed between dose levels and efficacy.</li><li>A Phase 3 study, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03445533?term=illuminate-301&amp;rank=1\" target=\"_blank\">ILLUMINATE-301</a>, evaluating tilsotolimod (IMO-2125) combined with with Bristol-Myers Squibb's Yervoy (ipilimumab) compared to Yervoy alone in melanoma patients resistant to anti-PD-1 treatment is currently recruiting subjects.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447766\" data-linked=\"Idera up 8% on early-stage tilsotolimod data\" data-tweet=\"$IDRA - Idera up 8% on early-stage tilsotolimod data https://seekingalpha.com/news/3447766-idera-up-8-on-early-stage-tilsotolimod-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3447766-idera-up-8-on-early-stage-tilsotolimod-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447757\" data-ts=\"1554214461\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BRFH\" target=\"_blank\">BRFH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447757-barfresh-food-slides-11-post-fy-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Barfresh Food slides 11% post FY results</a></h4><ul><li>Barfresh Food (<a href='https://seekingalpha.com/symbol/BRFH' title='Barfresh Food Group, Inc.'>OTCQB:BRFH</a> <font color=\"red\">-11%</font>) reported <a href=\"https://seekingalpha.com/pr/17461997-barfresh-provides-annual-2018-update-recent-business-progress\" target=\"_blank\">FY</a> revenue growth of 113.1% Y/Y to $4.24M.</li><li>Gross profit for FY18 <font color=\"green\">increased 600 bps</font> to 51%.</li><li>Operating loss improved 31% Y/Y to $6.1M, driven by higher gross profit margin on higher sales and lower G&amp;A expenses.</li><li>The Company had $1M of cash and $1.2M of inventory on its balance sheet.</li><li>During Q1 2019, the company has raised ~$4.3M of capital through the combination of a private placement of equity, and the cash exercise of existing warrants.</li><li>Over 350 school locations and 100 armed forces dining facilities were signed entering 2019.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3447542-barfresh-food-group-reports-fy-results\" target=\"_blank\">Barfresh Food Group reports FY results</a> (Apr. 01 2019)</li></ul><div class=\"tiny-share-widget\" data-id=\"3447757\" data-linked=\"Barfresh Food slides 11% post FY results\" data-tweet=\"$BRFH - Barfresh Food slides 11% post FY results https://seekingalpha.com/news/3447757-barfresh-food-slides-11-post-fy-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3447757-barfresh-food-slides-11-post-fy-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:14 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447755\" data-ts=\"1554214314\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TM\" target=\"_blank\">TM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447755-toyota-motor-u-s-sales-dropped-3_5-in-march\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Toyota Motor U.S. sales dropped 3.5% in March</a></h4><ul><li>Toyota (<a href='https://seekingalpha.com/symbol/TM' title='Toyota Motor Corporation'>TM</a> <font color='green'>+0.6%</font>) unit sales <a href=\"https://seekingalpha.com/pr/17463641-toyota-motor-north-america-reports-march-2019-sales\" target=\"_blank\">-3.5%</a> to 214,947 units vs. -2.6% forecast by Edmunds.</li><li>Q1 unit sales dropped 3.7% to 543,714 units.</li><li>Toyota division sales down 5.1% to 185,696 units.</li><li>Lexus division sales increased 8.2% to 29,249 units.</li><li>Total YARIS sales expanded 30.6% to 3,999 units.</li><li>Total Corolla sales decreased 22% to 24,479 units.</li><li>Camry sales slipped 4.7% to 33,615 units.</li><li>Prius sales declined 34.2% to 5,410 units.</li><li>On the SUV front, RAV4 sales -5.1% and Highlander sales -2.9% while Land Cruiser +21.3%.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447755\" data-linked=\"Toyota Motor U.S. sales dropped 3.5% in March\" data-tweet=\"$TM - Toyota Motor U.S. sales dropped 3.5% in March https://seekingalpha.com/news/3447755-toyota-motor-u-s-sales-dropped-3_5-in-march?source=tweet\" data-url=\"https://seekingalpha.com/news/3447755-toyota-motor-u-s-sales-dropped-3_5-in-march\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447744\" data-ts=\"1554213090\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WING\" target=\"_blank\">WING</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447744-wingstop-falls-after-guggenheim-cut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wingstop falls after Guggenheim cut</a></h4><ul> <li>Wingstop (<a href='https://seekingalpha.com/symbol/WING' title='Wingstop Inc.'>WING</a> <font color='red'>-4.9%</font>) drops sharply after Guggenheim Securities lowers the restaurant stock to a Neutral rating from Buy.</li> <li>Guggenheim drops earnings estimates on Wingstop with eyes on rising wing costs and the trading multiple amid the risk of slowing store growth.</li> <li>Shares of Wingstop are up 11% YTD.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3447744\" data-linked=\"Wingstop falls after Guggenheim cut\" data-tweet=\"$WING - Wingstop falls after Guggenheim cut https://seekingalpha.com/news/3447744-wingstop-falls-after-guggenheim-cut?source=tweet\" data-url=\"https://seekingalpha.com/news/3447744-wingstop-falls-after-guggenheim-cut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:51 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447741\" data-ts=\"1554212858\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MSFT\" target=\"_blank\">MSFT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447741-shopifyminus-2_8-microsoft-plans-competing-product\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Shopify -2.8% as Microsoft plans competing product</a></h4><ul><li>Shopify (NYSE:<a href='https://seekingalpha.com/symbol/SHOP' title='Shopify Inc.'>SHOP</a>) <font color=\"red\">drops 2.8%</font> after <a href=\"https://www.theinformation.com/articles/microsoft-considers-creating-a-shopify-competitor\" target=\"_blank\">The Information</a> reports Microsoft (NASDAQ:<a href='https://seekingalpha.com/symbol/MSFT' title='Microsoft Corporation'>MSFT</a>) wants to make a competing product.</li><li>Microsoft VP of retail and consumer goods Shelley Bransten says the tech giant is considering offering software tools that let retailers manage e-commerce sales.</li><li>Last month, Shopify shares were hit with the launch of <a href=\"https://seekingalpha.com/news/3444100-shopify-minus-3_5-percent-instagrams-checkout-competition\" target=\"_blank\">Instagram Checkout </a>and Square's<a href=\"https://seekingalpha.com/news/3444529-square-revamps-merchant-products-takes-shopify\" target=\"_blank\"> merchant product revamp</a> to compete.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447741\" data-linked=\"Shopify -2.8% as Microsoft plans competing product\" data-tweet=\"$MSFT $SHOP $SHOP - Shopify -2.8% as Microsoft plans competing product https://seekingalpha.com/news/3447741-shopifyminus-2_8-microsoft-plans-competing-product?source=tweet\" data-url=\"https://seekingalpha.com/news/3447741-shopifyminus-2_8-microsoft-plans-competing-product\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>50&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447736\" data-ts=\"1554212535\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447736-airline-investors-cheer-delta-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Airline investors cheer Delta results</a></h4><ul> <li>A lift in guidance by Delta Air Lines (<a href='https://seekingalpha.com/symbol/DAL' title='Delta Air Lines, Inc.'>DAL</a> <font color=\"green\">+4%</font>) is giving airline sector investors a reason to be confident, with some peers following Delta higher in early trading.</li> <li>Delta says it expects Q1 revenue growth of about 7% vs. +5% to +6% prior view and EPS of $0.85 to $0.95 vs. $0.70 to $0.90 prior view and $0.80 consensus.</li> <li>Delta's strong read could alleviate some of the anxiety over a Q1 that is being considered a disruptive period for the U.S. airline with the government shutdown impacting some bookings, the Boeing 737 Max crash and more system outages than normal.</li><li>Delta is due to report full Q1 results next week.</li> <li>On watch: Southwest Airlines (<a href='https://seekingalpha.com/symbol/LUV' title='Southwest Airlines Co.'>LUV</a> <font color=\"red\">-0.2%</font>), American Airlines (<a href='https://seekingalpha.com/symbol/AAL' title='American Airlines Group Inc.'>AAL</a> <font color=\"green\">+0.9%</font>), Hawaiian Holdings (<a href='https://seekingalpha.com/symbol/HA' title='Hawaiian Holdings, Inc.'>HA</a> <font color=\"red\">-0.8%</font>), Alaska Air Group (<a href='https://seekingalpha.com/symbol/ALK' title='Alaska Air Group, Inc.'>ALK</a>), Mesa Air (<a href='https://seekingalpha.com/symbol/MESA' title='Mesa Air Group, Inc.'>MESA</a> <font color=\"green\">+1.7%</font>), Spirit Airlines (<a href='https://seekingalpha.com/symbol/SAVE' title='Spirit Airlines, Inc.'>SAVE</a> <font color=\"red\">-0.4%</font>), United Continental (<a href='https://seekingalpha.com/symbol/UAL' title='United Continental Holdings, Inc.'>UAL</a> <font color=\"green\">+2.9%</font>), JetBlue (<a href='https://seekingalpha.com/symbol/JBLU' title='JetBlue Airways Corporation'>JBLU</a>), SkyWest (<a href='https://seekingalpha.com/symbol/SKYW' title='SkyWest, Inc.'>SKYW</a> <font color=\"red\">-0.6%</font>).</li><li>Related ETF: <a href='https://seekingalpha.com/symbol/JETS' title='U.S. Global Jets ETF'>JETS</a>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3447717-delta-announces-march-traffic-shares-5-percent-premarket\" target=\"_blank\">Delta announces March traffic, shares up 5% premarket</a> (April 2)</li>    </ul><div class=\"tiny-share-widget\" data-id=\"3447736\" data-linked=\"Airline investors cheer Delta results\" data-tweet=\"$DAL $LUV $AAL - Airline investors cheer Delta results https://seekingalpha.com/news/3447736-airline-investors-cheer-delta-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3447736-airline-investors-cheer-delta-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>34&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447734\" data-ts=\"1554212395\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SGMO\" target=\"_blank\">SGMO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447734-sangamo-expands-manufacturing-capacity-brammer-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sangamo expands manufacturing capacity with Brammer deal</a></h4><ul><li>Sangamo Therapeutics (<a href='https://seekingalpha.com/symbol/SGMO' title='Sangamo Therapeutics, Inc.'>SGMO</a> <font color=\"green\">+35.4%</font>) inks an <a href=\"https://seekingalpha.com/pr/17462626-sangamo-announces-agreement-securing-access-large-scale-commercial-grade-manufacturing\" target=\"_blank\">agreement </a>with gene therapy contract developer and manufacturer Brammer Bio securing access to large-scale adeno-associated virus &#40;AAV&#41; manufacturing, enabling commercial-grade production runs for gene therapy products like ST-920, the company's candidate for Fabry disease.</li><li>Financial terms remain confidential.</li><li>Shares are up following the release of <a href=\"https://seekingalpha.com/news/3447662-sangamo-7-percent-premarket-positive-hemophilia-gene-therapy-data\" target=\"_blank\">positive data</a> on its hemophilia gene therapy candidate SB-525.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447734\" data-linked=\"Sangamo expands manufacturing capacity with Brammer deal\" data-tweet=\"$SGMO - Sangamo expands manufacturing capacity with Brammer deal https://seekingalpha.com/news/3447734-sangamo-expands-manufacturing-capacity-brammer-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3447734-sangamo-expands-manufacturing-capacity-brammer-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447732\" data-ts=\"1554211998\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNH\" target=\"_blank\">SNH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447732-senior-housing-properties-plunges-on-five-star-deal-dividend-cut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Senior Housing Properties plunges on Five Star deal, dividend cut</a></h4><ul><li>Senior Housing Properties (NASDAQ:<a href='https://seekingalpha.com/symbol/SNH' title='Senior Housing Properties Trust'>SNH</a>) <font color=\"red\">drops 21% </font>after its restructured arrangement with Five Star Senior Living (NASDAQ:<a href='https://seekingalpha.com/symbol/FVE' title='Five Star Senior Living Inc.'>FVE</a>) leads to Senior Housing <a href=\"https://seekingalpha.com/filing/4428958\" target=\"_blank\">cutting its annual dividend </a>to an expected 55 cents-65 cents per share.</li><li>SNH also expects to sell properties valued at up to $900M to achieve a debt-to-adjusted EBITDA ratio of about 6.0x by the end of 2019.</li><li>As part of the deal, SNH will increase its ownership in Five Star to ~34% from its current 8.3% stake; SNH holders will get a right to receive FVE shares, resulting in SNH holders owning ~51% of Five Star.</li><li>SNH says shareholders' Five Star holdings may help compensate for the lower dividend rate.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3447647-five-star-senior-living-restructures-arrangements-senior-housing\" target=\"_blank\">Five Star Senior Living restructures arrangements with Senior Housing</a> (April 2)</li></ul><div class=\"tiny-share-widget\" data-id=\"3447732\" data-linked=\"Senior Housing Properties plunges on Five Star deal, dividend cut\" data-tweet=\"$SNH $SNH $FVE - Senior Housing Properties plunges on Five Star deal, dividend cut https://seekingalpha.com/news/3447732-senior-housing-properties-plunges-on-five-star-deal-dividend-cut?source=tweet\" data-url=\"https://seekingalpha.com/news/3447732-senior-housing-properties-plunges-on-five-star-deal-dividend-cut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447726\" data-ts=\"1554211558\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SES\" target=\"_blank\">SES</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447726-synthesis-energy-engages-advisors-to-explore-strategic-alternatives\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Synthesis Energy engages advisors to explore strategic alternatives</a></h4><ul><li>Synthesis Energy Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/SES' title='Synthesis Energy Systems, Inc.'>SES</a>) <font color=\"green\">+4.7%</font> pre-market after saying it has engaged financial advisors to <a href=\"https://seekingalpha.com/pr/17462691-synthesis-energy-systems-engages-financial-advisors-evaluate-strategic-financing-alternatives\" target=\"_blank\">evaluate strategic alternatives</a> and financing options focused on maximizing shareholder value.</li><li>SES says alternatives could include a strategic merger, a sale of all or part of the company, a recapitalization and/or a financing consisting of equity and/or debt securities.</li><li>SES says its board has not set a definitive timetable for completion of the evaluation.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447726\" data-linked=\"Synthesis Energy engages advisors to explore strategic alternatives\" data-tweet=\"$SES - Synthesis Energy engages advisors to explore strategic alternatives https://seekingalpha.com/news/3447726-synthesis-energy-engages-advisors-to-explore-strategic-alternatives?source=tweet\" data-url=\"https://seekingalpha.com/news/3447726-synthesis-energy-engages-advisors-to-explore-strategic-alternatives\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:25 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447723\" data-ts=\"1554211286\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447723-mnkd-ttm-among-premarket-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MNKD, TTM among premarket gainers</a></h4><ul><li>ADMA Biologics (NASDAQ:<a href='https://seekingalpha.com/symbol/ADMA' title='ADMA Biologics, Inc.'>ADMA</a>) <font color=\"green\">+46%</font> as FDA <a href=\"https://seekingalpha.com/news/3447646-fda-approves-adma-biologics-asceniv-shares-46-percent-premarket\" target=\"_blank\">approves</a> ADMA Biologics' ASCENIV.</li><li>Sangamo Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SGMO' title='Sangamo Therapeutics, Inc.'>SGMO</a>) <font color=\"green\">+46%</font> on positive hemophilia A gene therapy <a href=\"https://seekingalpha.com/news/3447662-sangamo-7-percent-premarket-positive-hemophilia-gene-therapy-data\" target=\"_blank\">data</a>.</li><li>Riot Blockchain (NASDAQ:<a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a>) <font color=\"green\">+36%</font>.</li><li>EDAP TMS S.A. (NASDAQ:<a href='https://seekingalpha.com/symbol/EDAP' title='EDAP TMS S.A.'>EDAP</a>) <font color=\"green\">+30%</font> on Q4 <a href=\"https://seekingalpha.com/news/3447507-edap-tms-s-beats-revenue\" target=\"_blank\">earnings</a>.</li><li>Safe-T Group (NASDAQ:<a href='https://seekingalpha.com/symbol/SFET' title='Safe-T Group Ltd'>SFET</a>) <font color=\"green\">+18%</font> on <a href=\"https://seekingalpha.com/pr/17462441-safe-t-identified-single-vendor-receives-order-government-ministry-israel\" target=\"_blank\">order</a> from a government ministry in Israel.</li><li>AVEO Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/AVEO' title='AVEO Pharmaceuticals, Inc.'>AVEO</a>) <font color=\"green\">+15%</font> after <a href=\"https://seekingalpha.com/news/3447567-aveo-plus-22_5-percent-positive-results-aml-trial\" target=\"_blank\">positive results</a> from AML trial.</li><li>Xunlei (NASDAQ:<a href='https://seekingalpha.com/symbol/XNET' title='Xunlei Limited'>XNET</a>) <font color=\"green\">+12%</font>.</li><li>Dare Bioscience (NASDAQ:<a href='https://seekingalpha.com/symbol/DARE' title='Daré Bioscience, Inc.'>DARE</a>) <font color=\"green\">+10%</font>.</li><li>Achieve Life Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/ACHV' title='Achieve Life Sciences, Inc.'>ACHV</a>) <font color=\"green\">+10%</font> on <a href=\"https://seekingalpha.com/news/3447641-achieve-life-sciences-plus-13-percent-dsmc-review-phase-2b-orcaminus-1-trial\" target=\"_blank\">DSMC review</a> of phase 2b ORCA-1 trial.</li><li>AmeriGas Partners, L.P. (NYSE:<a href='https://seekingalpha.com/symbol/APU' title='AmeriGas Partners, L.P.'>APU</a>) <font color=\"green\">+10%</font>. as UGI Corp <a href=\"https://seekingalpha.com/news/3447639-ugi-buy-100-percent-amerigas-partners-cuts-full-year-earnings-guidance\" target=\"_blank\">agrees to acquire</a> the 69.2M common units of APU.</li><li>Ovid Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/OVID' title='Ovid Therapeutics Inc.'>OVID</a>) <font color=\"green\">+9%</font>.</li><li>Lamb Weston Holdings (NYSE:<a href='https://seekingalpha.com/symbol/LW' title='Lamb Weston Holdings, Inc.'>LW</a>) <font color=\"green\">+7%</font> on <a href=\"https://seekingalpha.com/news/3447701-lamb-weston-beats-0_12-beats-revenue\" target=\"_blank\">Q3 earnings</a>.</li><li>Mexco Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/MXC' title='Mexco Energy Corporation'>MXC</a>) <font color=\"green\">+7%</font>.</li><li>Overstock.com (NASDAQ:<a href='https://seekingalpha.com/symbol/OSTK' title='Overstock.com, Inc.'>OSTK</a>) <font color=\"green\">+7%</font> after <a href=\"https://seekingalpha.com/news/3447706-overstock-com-plus-5-percent-bitcoin-wakes\" target=\"_blank\">Bitcoin wakes up</a>.</li><li>Tata Motors (NYSE:<a href='https://seekingalpha.com/symbol/TTM' title='Tata Motors Limited'>TTM</a>) <font color=\"green\">+6%</font>.</li><li>AquaBounty Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/AQB' title='AquaBounty Technologies, Inc.'>AQB</a>) <font color=\"green\">+5%</font> as Environment and Climate Change Canada has <a href=\"https://seekingalpha.com/pr/17462704-aquabounty-technologies-inc-environment-climate-change-canada-approves-rollo-bay-facility\" target=\"_blank\">approved</a> the Rollo Bay production facility for the commercial manufacture and grow-out of AquAdvantage Salmon.</li><li>MannKind (NASDAQ:<a href='https://seekingalpha.com/symbol/MNKD' title='MannKind Corporation'>MNKD</a>) <font color=\"green\">+5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447723\" data-linked=\"MNKD, TTM among premarket gainers\" data-tweet=\"$ADMA $SGMO $RIOT - MNKD, TTM among premarket gainers https://seekingalpha.com/news/3447723-mnkd-ttm-among-premarket-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3447723-mnkd-ttm-among-premarket-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:21 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447722\" data-ts=\"1554211202\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLVS\" target=\"_blank\">CLVS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447722-clovis-up-3-premarket-on-rubraca-data-in-pancreatic-cancer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Clovis up 3% premarket on Rubraca data in pancreatic cancer</a></h4><ul><li>Clovis Oncology (NASDAQ:<a href='https://seekingalpha.com/symbol/CLVS' title='Clovis Oncology, Inc.'>CLVS</a>) is up <font color=\"green\">3%</font> premarket on light volume in reaction to <a href=\"https://seekingalpha.com/pr/17463105-clovis-oncology-announces-interim-results-rubraca-rucaparib-phase-2-study-advanced-pancreatic\" target=\"_blank\">interim results</a> from an investigator-initiated Phase 2 study evaluating Rubraca (rucaparib) as first-line maintenance therapy in pancreatic cancer patients following induction with platinum-based chemo. The data were presented at AACR in Atlanta.</li><li>Preliminary results suggest that treatment with the PARP inhibitor provides a disease control benefit in patients with BRCA1, BRCA2 or PALB2 mutations, a population representing 5 - 8% of pancreatic cancer cases.</li><li>The primary endpoint of the 42-subject study is progression-free survival &#40;PFS&#41;. In 19 evaluable patients, median PFS was 9.1 months from the start of Rubraca treatment. Median overall survival has not been reached. The response rate was 36.8% (n=7/19), including one complete responder. The disease control rate (responders + stable cancer) was 89.5% (n=17/19) at week 8.</li><li>Pancreatic cancer is one of the most treatment-resistant cancers with a five-year survival rate of only 8.5%.</li><li>GlaxoSmithKline (NYSE:<a href='https://seekingalpha.com/symbol/GSK' title='GlaxoSmithKline plc'>GSK</a>), recent acquirer of PARP inhibitor developer TESARO, is up <font color=\"green\">1%</font> premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447722\" data-linked=\"Clovis up 3% premarket on Rubraca data in pancreatic cancer\" data-tweet=\"$CLVS $GSK - Clovis up 3% premarket on Rubraca data in pancreatic cancer https://seekingalpha.com/news/3447722-clovis-up-3-premarket-on-rubraca-data-in-pancreatic-cancer?source=tweet\" data-url=\"https://seekingalpha.com/news/3447722-clovis-up-3-premarket-on-rubraca-data-in-pancreatic-cancer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447720\" data-ts=\"1554211066\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447720-wba-evok-and-ugi-among-premarket-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WBA, EVOK and UGI among premarket losers</a></h4><ul><li>Energy Focus (NASDAQ:<a href='https://seekingalpha.com/symbol/EFOI' title='Energy Focus, Inc.'>EFOI</a>) <font color=\"red\">-52%</font> on <a href=\"https://seekingalpha.com/news/3447520-energy-focus-misses-0_10-misses-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>Evoke Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/EVOK' title='Evoke Pharma, Inc.'>EVOK</a>) <font color=\"red\">-46%</font> on <a href=\"https://seekingalpha.com/news/3447618-evoke-pharma-receives-crl-gimoti-nda-shares-38-percent-premarket\" target=\"_blank\">receiving</a> CRL for Gimoti NDA.</li><li>Apyx Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/APYX' title='Apyx Medical Corporation'>APYX</a>) <font color=\"red\">-39%</font> on <a href=\"https://seekingalpha.com/news/3447481-apyx-16-percent-hours-withdrawal-renuvion-application\" target=\"_blank\">withdrawal</a> of Renuvion application.</li><li>Senior Housing Properties Trust (NASDAQ:<a href='https://seekingalpha.com/symbol/SNH' title='Senior Housing Properties Trust'>SNH</a>) <font color=\"red\">-22%</font> after Five Star Senior Living <a href=\"https://seekingalpha.com/news/3447647-five-star-senior-living-restructures-arrangements-senior-housing\" target=\"_blank\">restructures</a> business arrangements.</li><li>Pulmatrix (NASDAQ:<a href='https://seekingalpha.com/symbol/PULM' title='Pulmatrix, Inc.'>PULM</a>) <font color=\"red\">-12%</font>.</li><li>NewLink Genetics (NASDAQ:<a href='https://seekingalpha.com/symbol/NLNK' title='NewLink Genetics Corporation'>NLNK</a>) <font color=\"red\">-10%</font>.</li><li>Walgreens Boots Alliance (NASDAQ:<a href='https://seekingalpha.com/symbol/WBA' title='Walgreens Boots Alliance, Inc.'>WBA</a>) <font color=\"red\">-10%</font> on <a href=\"https://seekingalpha.com/news/3447631-walgreens-boots-misses-0_08-misses-revenue\" target=\"_blank\">Q2 earnings</a>.</li><li>TrovaGene (NASDAQ:<a href='https://seekingalpha.com/symbol/TROV' title='TrovaGene, Inc.'>TROV</a>) <font color=\"red\">-9%</font> on presenting <a href=\"https://seekingalpha.com/pr/17462833-early-data-phase-2-trial-indicates-activity-onvansertib-prostate-cancer-patients-showing\" target=\"_blank\">data</a> from Phase 2 study evaluating Onvansertib in combination with Zytiga in patients with mCRPC.</li><li>Cellcom Israel (NYSE:<a href='https://seekingalpha.com/symbol/CEL' title='Cellcom Israel Ltd.'>CEL</a>) <font color=\"red\">-7%</font>.</li><li>UGI (NYSE:<a href='https://seekingalpha.com/symbol/UGI' title='UGI Corporation'>UGI</a>) <font color=\"red\">-7%</font> on <a href=\"https://seekingalpha.com/news/3447639-ugi-buy-100-percent-amerigas-partners-cuts-full-year-earnings-guidance\" target=\"_blank\">acquiring</a> 69.2M common units of AmeriGas Partners.</li><li>PhaseBio Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/PHAS' title='PhaseBio Pharmaceuticals, Inc.'>PHAS</a>) <font color=\"red\">-7%</font>.</li><li>Altimmune (NASDAQ:<a href='https://seekingalpha.com/symbol/ALT' title='Altimmune, Inc.'>ALT</a>) <font color=\"red\">-6%</font> on <a href=\"https://seekingalpha.com/news/3447487-altimmune-reports-fy-results\" target=\"_blank\">FY results</a>.</li><li>ShiftPixy (NASDAQ:<a href='https://seekingalpha.com/symbol/PIXY' title='ShiftPixy, Inc.'>PIXY</a>) <font color=\"red\">-6%</font> on registering up to 10.2M shares to <a href=\"https://seekingalpha.com/news/3447709-shiftpixy-files-sell-shares-holders\" target=\"_blank\">sell</a> on behalf of holders.</li><li>Celldex Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CLDX' title='Celldex Therapeutics, Inc.'>CLDX</a>) <font color=\"red\">-5%</font>.</li><li>Advaxis (NASDAQ:<a href='https://seekingalpha.com/symbol/ADXS' title='Advaxis, Inc.'>ADXS</a>) <font color=\"red\">-6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3447720\" data-linked=\"WBA, EVOK and UGI among premarket losers\" data-tweet=\"$EFOI $EVOK $APYX - WBA, EVOK and UGI among premarket losers https://seekingalpha.com/news/3447720-wba-evok-and-ugi-among-premarket-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3447720-wba-evok-and-ugi-among-premarket-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447710\" data-ts=\"1554210050\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OCUL\" target=\"_blank\">OCUL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447710-fda-accepts-ocular-application-for-expanded-use-of-dextenza\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA accepts Ocular application for expanded use of Dextenza</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/17463067-ocular-therapeutix-announces-notification-fda-acceptance-supplemental-new-drug-submission\" target=\"_blank\">accepts for review</a> Ocular Therapeutix's (NASDAQ:<a href='https://seekingalpha.com/symbol/OCUL' title='Ocular Therapeutix, Inc.'>OCUL</a>) supplemental marketing application seeking approval to use DEXTENZA (dexamethasone ophthalmic insert) to treat ocular inflammation following ophthalmic surgery. The agency's action date is November 10.</li><li>The FDA approved DEXTENZA in December 2018 for ocular pain following ophthalmic surgery.</li><li>Shares are up <font color=\"green\">2%</font> premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447710\" data-linked=\"FDA accepts Ocular application for expanded use of Dextenza\" data-tweet=\"$OCUL - FDA accepts Ocular application for expanded use of Dextenza https://seekingalpha.com/news/3447710-fda-accepts-ocular-application-for-expanded-use-of-dextenza?source=tweet\" data-url=\"https://seekingalpha.com/news/3447710-fda-accepts-ocular-application-for-expanded-use-of-dextenza\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447706\" data-ts=\"1554209667\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OSTK\" target=\"_blank\">OSTK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447706-overstock-complus-5-after-bitcoin-wakes-up\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Overstock.com +5% after Bitcoin wakes up</a></h4><ul> <li>Overstock.com (NASDAQ:<a href='https://seekingalpha.com/symbol/OSTK' title='Overstock.com, Inc.'>OSTK</a>) is <font color=\"green\">up 5.12%</font> in premarket action after Bitcoin shot higher to briefly crack the $5K mark again.</li> <li>The Bitcoin rally is being <a href=\"https://www.cnbc.com/2019/04/02/bitcoin-rallies-14percent-to-its-highest-level-since-november-last-year.html\" target=\"_blank\">attributed</a> by analysts to resistance at the $4.2K level.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3447607-bitcoin-soars-5k-bitstamp-exchange\" target=\"_blank\">Bitcoin soars to $5K on Bitstamp exchange</a> (April 2)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3447706\" data-linked=\"Overstock.com +5% after Bitcoin wakes up\" data-tweet=\"$OSTK - Overstock.com +5% after Bitcoin wakes up https://seekingalpha.com/news/3447706-overstock-complus-5-after-bitcoin-wakes-up?source=tweet\" data-url=\"https://seekingalpha.com/news/3447706-overstock-complus-5-after-bitcoin-wakes-up\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447705\" data-ts=\"1554209658\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LYFT\" target=\"_blank\">LYFT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447705-analyst-lyft-valuation-requires-leap-of-faith\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analyst: Lyft valuation requires &quot;leap of faith&quot;</a></h4><ul><li>Seaport Global Securities initiates Lyft (NASDAQ:<a href='https://seekingalpha.com/symbol/LYFT' title='Lyft, Inc.'>LYFT</a>) at Sell with a $42 PT saying \"a big leap of faith\" is required to justify the current market valuation.</li><li>Analyst Michael Ward says the valuation depends on millennials and later generations forgoing vehicle ownership and instead relying on a ridesharing service.</li><li>Ward's target implies a 39% downside from yesterday's closing price. Lyft shares dropped nearly 12% yesterday, the second day of trading.</li><li>Lyft shares are <font color=\"red\">down 4%</font> pre-market to $66.24.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447705\" data-linked=\"Analyst: Lyft valuation requires &quot;leap of faith&quot;\" data-tweet=\"$LYFT - Analyst: Lyft valuation requires &quot;leap of faith&quot; https://seekingalpha.com/news/3447705-analyst-lyft-valuation-requires-leap-of-faith?source=tweet\" data-url=\"https://seekingalpha.com/news/3447705-analyst-lyft-valuation-requires-leap-of-faith\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447703\" data-ts=\"1554209326\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LW\" target=\"_blank\">LW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447703-lamb-westonplus-7-after-strong-quarter-guidance-boost\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lamb Weston +7% after strong quarter, guidance boost</a></h4><ul> <li>Lamb Weston (NYSE:<a href='https://seekingalpha.com/symbol/LW' title='Lamb Weston Holdings, Inc.'>LW</a>) shoots higher after the company tops <a href=\"https://seekingalpha.com/pr/17463098-lamb-weston-reports-fiscal-third-quarter-2019-results-updates-full-year-outlook\" target=\"_blank\">FQ3</a> estimates and lifts full-year guidance.</li> <li>Volume was up 4.0% during the quarter and price/mix impacted sales by 3.0%. Gross margin was reported at 29.5% of sales vs. 28.1% a year ago and 27.4% consensus.</li> <li>CEO update: \"Strong execution by our commercial teams drove an overall good balance of price/mix improvement and volume growth, while our supply chain team generated operating efficiencies and cost savings to expand gross margins. In addition, we continued to make good progress on our initiatives to invest in production capacity, as well as operating, sales and product innovation capabilities that we believe will support sustainable, profitable growth over the long term.\"</li> <li>Looking ahead, Lamb Weston expects sales to increase at a high single digit rate vs. prior guidance for a mid-to-high single digit rate. Adjusted EBITDA is expected to land in a range of $895M to $905M for the full year vs. $870M to $880M prior range.</li> <li>LW <font color=\"green\">+7.05%</font> premarket to $79.14.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3447701-lamb-weston-beats-0_12-beats-revenue\" target=\"_blank\">Lamb Weston beats by $0.12, beats on revenue</a> (April 2)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3447703\" data-linked=\"Lamb Weston +7% after strong quarter, guidance boost\" data-tweet=\"$LW - Lamb Weston +7% after strong quarter, guidance boost https://seekingalpha.com/news/3447703-lamb-westonplus-7-after-strong-quarter-guidance-boost?source=tweet\" data-url=\"https://seekingalpha.com/news/3447703-lamb-westonplus-7-after-strong-quarter-guidance-boost\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447702\" data-ts=\"1554208673\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ISRG\" target=\"_blank\">ISRG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447702-jefferies-likes-quest-and-labcorp-in-premarket-analyst-action\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jefferies likes Quest and LabCorp in premarket analyst action</a></h4><ul><li>Intuitive Surgical (NASDAQ:<a href='https://seekingalpha.com/symbol/ISRG' title='Intuitive Surgical, Inc.'>ISRG</a>) initiated with Buy rating and $630 (9% upside) price target. Shares up a fraction premarket.</li><li>AtriCure (NASDAQ:<a href='https://seekingalpha.com/symbol/ATRC' title='AtriCure, Inc.'>ATRC</a>) upgraded to Buy with a $35 (28% upside) price target at BTIG Research.</li><li>Quest Diagnostics (NYSE:<a href='https://seekingalpha.com/symbol/DGX' title='Quest Diagnostics Incorporated'>DGX</a>) upgraded to Buy at Jefferies citing upside from the rollout of UnitedHealth Group's preferred lab network. Shares up <font color=\"green\">1%</font> premarket. Both DGX and LH have ~$1B of UNH's $8B annual lab spend so they should see market share gains.</li><li>LabCorp (NYSE:<a href='https://seekingalpha.com/symbol/LH' title='Laboratory Corporation of America Holdings'>LH</a>) upgraded to Buy at Jefferies citing the upside from the rollout of UnitedHealth Group's preferred lab network. Shares up <font color=\"green\">1% </font>premarket.</li><li>Pacific Biosciences of California (NASDAQ:<a href='https://seekingalpha.com/symbol/PACB' title='Pacific Biosciences of California, Inc.'>PACB</a>) downgraded to Equal Weight at Stephens. Shares down <font color=\"red\">1%</font> premarket.</li><li>Qiagen (NYSE:<a href='https://seekingalpha.com/symbol/QGEN' title='QIAGEN N.V.'>QGEN</a>) downgraded to Neutral at Invest Securities SA. Shares up <font color=\"green\">1%</font> premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447702\" data-linked=\"Jefferies likes Quest and LabCorp in premarket analyst action\" data-tweet=\"$ISRG $ATRC $DGX - Jefferies likes Quest and LabCorp in premarket analyst action https://seekingalpha.com/news/3447702-jefferies-likes-quest-and-labcorp-in-premarket-analyst-action?source=tweet\" data-url=\"https://seekingalpha.com/news/3447702-jefferies-likes-quest-and-labcorp-in-premarket-analyst-action\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447701\" data-ts=\"1554208489\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LW\" target=\"_blank\">LW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447701-lamb-weston-beats-0_12-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lamb Weston beats by $0.12, beats on revenue</a></h4><ul><li>Lamb Weston (NYSE:<a href='https://seekingalpha.com/symbol/LW' title='Lamb Weston Holdings, Inc.'>LW</a>): Q3 Non-GAAP EPS of $0.95 <span style=\"color:green\">beats by $0.12</span>; GAAP EPS of $0.95.</li><li>Revenue of $926.8M (+7.3% Y/Y) <font color=\"green\">beats by $28.34M</font>.</li><li>Shares <font color=\"green\">+6.25%</font> PM.</li><li><a href=\"https://seekingalpha.com/pr/17463098-lamb-weston-reports-fiscal-third-quarter-2019-results-updates-full-year-outlook\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3447701\" data-linked=\"Lamb Weston beats by $0.12, beats on revenue\" data-tweet=\"$LW - Lamb Weston beats by $0.12, beats on revenue https://seekingalpha.com/news/3447701-lamb-weston-beats-0_12-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3447701-lamb-weston-beats-0_12-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:34 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447699\" data-ts=\"1554208361\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEUM\" target=\"_blank\">TEUM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447699-pareteumplus-2-on-22m-blockchain-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pareteum +2% on $22M blockchain deal</a></h4><ul><li>Pareteum (NASDAQ:<a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a>) <a href=\"https://seekingalpha.com/pr/17462614-pareteum-wins-22-million-contract-digital-currency-wi-fi-provider\" target=\"_blank\">announces</a> a new contract with a digital currency Wi-Fi provider that is worth more than $22M over 36 months.</li><li>The customer is building a global blockchain-based Wi-Fi sharing community. Members can mine tokens by sharing their Wi-Fi.</li><li>TEUM shares are <font color=\"green\">up 2.2%</font> pre-market to $4.64.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447699\" data-linked=\"Pareteum +2% on $22M blockchain deal\" data-tweet=\"$TEUM - Pareteum +2% on $22M blockchain deal https://seekingalpha.com/news/3447699-pareteumplus-2-on-22m-blockchain-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3447699-pareteumplus-2-on-22m-blockchain-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447697\" data-ts=\"1554208329\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TAP\" target=\"_blank\">TAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447697-big-gains-seen-for-molson-coors\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Big gains seen for Molson Coors</a></h4><ul> <li>Molson Coors (NYSE:<a href='https://seekingalpha.com/symbol/TAP' title='Molson Coors Brewing Company'>TAP</a>) falls on a <a href=\"https://www.marketwatch.com/story/four-solid-stocks-whose-recent-hard-times-mean-theyre-potential-bargains-2019-04-02\" target=\"_blank\">short list</a> from Kovitz Investment Group of \"high-conviction\" picks of companies that appear to be trading at big discounts to fair value estimates.</li> <li>Kovitz has a target of $84 on Molson Coors to rep ~40% upside potential.</li> <li>\"Basically, this is also a margin-improvement story. Everybody is concerned that beer is a declining category,\u201d Burnstine said. But he believes the industry\u2019s problems are \u201cmore cyclical ... interest [in beer] ebbs and flows over time,\" Kovitz' Bob Burnstine notes to MarketWatch.</li> <li>The firm expects cost-cutting to feed TAP's bottom line even with the top line growing slowly.</li> <li>TAP <font color=\"green\">+1.04%</font> premarket to $61.00.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3447697\" data-linked=\"Big gains seen for Molson Coors\" data-tweet=\"$TAP - Big gains seen for Molson Coors https://seekingalpha.com/news/3447697-big-gains-seen-for-molson-coors?source=tweet\" data-url=\"https://seekingalpha.com/news/3447697-big-gains-seen-for-molson-coors\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447691\" data-ts=\"1554207865\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DPLO\" target=\"_blank\">DPLO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447691-walgreens-boots-fq2-weighs-on-drug-wholesalers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Walgreens Boots FQ2 weighs on drug wholesalers</a></h4><ul><li>Drug distributors are under mild pressure premarket in reaction to Walgreens Boots Alliance's <a href=\"https://seekingalpha.com/news/3447653-walgreens-boots-7-percent-fiscal-q2-results\" target=\"_blank\">FQ2 miss</a> and soft guidance.</li><li>Selected tickers: Diplomat Pharmacy (NYSE:<a href='https://seekingalpha.com/symbol/DPLO' title='Diplomat Pharmacy, Inc.'>DPLO</a>)(<font color=\"red\">-2%</font>); McKesson (NYSE:<a href='https://seekingalpha.com/symbol/MCK' title='McKesson Corporation'>MCK</a>)(down a fraction); Cardinal Health (NYSE:<a href='https://seekingalpha.com/symbol/CAH' title='Cardinal Health, Inc.'>CAH</a>)(down a fraction).</li><li>Retail competitor Rite Aid (NYSE:<a href='https://seekingalpha.com/symbol/RAD' title='Rite Aid Corporation'>RAD</a>) is up <font color=\"green\">1%</font> on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447691\" data-linked=\"Walgreens Boots FQ2 weighs on drug wholesalers\" data-tweet=\"$DPLO $MCK $CAH - Walgreens Boots FQ2 weighs on drug wholesalers https://seekingalpha.com/news/3447691-walgreens-boots-fq2-weighs-on-drug-wholesalers?source=tweet\" data-url=\"https://seekingalpha.com/news/3447691-walgreens-boots-fq2-weighs-on-drug-wholesalers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447675\" data-ts=\"1554206682\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DIS\" target=\"_blank\">DIS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447675-rosenblatt-initiates-disney-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rosenblatt initiates Disney at Buy</a></h4><ul><li>Rosenblatt has <a href=\"https://www.streetinsider.com/Analyst+Comments/Rosenblatt+Starts+Walt+Disney+%28DIS%29+at+Buy/15325450.html\" target=\"_blank\">started</a> coverage on Walt Disney (NYSE:<a href='https://seekingalpha.com/symbol/DIS' title='The Walt Disney Company'>DIS</a>) with a Buy rating and price target of $150.</li><li>Analyst Mark Zgutowicz said the media giant's current valuation is \"compelling\" as its Disney+ service will likely be successful.</li><li>DIS <font color=\"green\">+0.7%</font> premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3447675\" data-linked=\"Rosenblatt initiates Disney at Buy\" data-tweet=\"$DIS - Rosenblatt initiates Disney at Buy https://seekingalpha.com/news/3447675-rosenblatt-initiates-disney-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3447675-rosenblatt-initiates-disney-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>28&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447672\" data-ts=\"1554206471\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EGO\" target=\"_blank\">EGO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447672-eldorado-gold-resumes-full-operations-kisladag-mine\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eldorado Gold resumes full operations at Kisladag mine</a></h4><ul><li>Eldorado Gold (NYSE:<a href='https://seekingalpha.com/symbol/EGO' title='Eldorado Gold Corporation'>EGO</a>) <font color=\"green\">+2.2%</font> pre-market after saying it <a href=\"https://seekingalpha.com/pr/17462587-eldorado-gold-announces-resumption-crushing-stacking-kisladag\" target=\"_blank\">resumed mining, crushing and placing of ore</a> at its Kisladag mine in Turkey, in line with its announcement earlier this year that it will drop a milling project at the mine in favor of heap leaching.</li><li>EGO says further testwork is underway to determine the effects of 250-day leach  cycles on deeper material, with results expected to be  available in late 2019 or early 2020.</li><li>With the resumption of operations, EGO says it is prepared to  deliver on its 2019 Kisladag production guidance of 145K-165K oz. at a  cash cost of $570-$620/oz., increasing in 2020 to 240K-260K oz.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447672\" data-linked=\"Eldorado Gold resumes full operations at Kisladag mine\" data-tweet=\"$EGO - Eldorado Gold resumes full operations at Kisladag mine https://seekingalpha.com/news/3447672-eldorado-gold-resumes-full-operations-kisladag-mine?source=tweet\" data-url=\"https://seekingalpha.com/news/3447672-eldorado-gold-resumes-full-operations-kisladag-mine\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447671\" data-ts=\"1554206467\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SONO\" target=\"_blank\">SONO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447671-sonos-gains-on-new-street-high-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sonos gains on new Street-high target</a></h4><ul><li>D.A. Davidson starts Sonos (NASDAQ:<a href='https://seekingalpha.com/symbol/SONO' title='Sonos, Inc.'>SONO</a>) at Buy with a Street-high $20 target citing an investor misunderstanding of the business that creates a \"compelling buying opportunity.\"</li><li>Analyst Tom Forte says investors fail to recognize the company's hardware and software expertise and growth potential.</li><li>Forte says Sonos has \"open-ended possibilities to advance its efforts in the connected home and audio segments.\"</li><li>Sonos shares are <font color=\"green\">up 1.4%</font> pre-market to $10.69.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447671\" data-linked=\"Sonos gains on new Street-high target\" data-tweet=\"$SONO - Sonos gains on new Street-high target https://seekingalpha.com/news/3447671-sonos-gains-on-new-street-high-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3447671-sonos-gains-on-new-street-high-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447664\" data-ts=\"1554205915\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ANGO\" target=\"_blank\">ANGO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447664-angiodynamics-down-7-on-fiscal-q3-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AngioDynamics down 7% on fiscal Q3 results</a></h4><ul><li>AngioDynamics (<a href='https://seekingalpha.com/symbol/ANGO' title='AngioDynamics, Inc.'>ANGO</a>) <a href=\"https://seekingalpha.com/news/3420620-angiodynamics-boots-q2-revenues-6-percent-non-gaap-eps-29-percent\" target=\"_blank\">Q3 results</a>: Revenues: $86.3M (+2.9%).</li><li>Net Income: $0.8M (-94.3%); EPS: $0.02 (-94.6%); Non-GAAP EPS: $0.19 (-17.4%); Non-GAAP Net Income: $7.4M (-14.9%); Quick Assets: $41.7M (-44.7%); CF Ops: $12.4M (-29.1%).</li><li><strong>FY 2019 Guidance</strong>: Net Sales: $354M - 359M (unch); Non-GAAP EPS: $0.82 - 0.86 (unch); FCF: $26M - 31M (unch).</li><li>Shares are down <font color=\"red\">7%</font> premarket.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3447633-angiodynamics-misses-0_02-misses-revenue\" target=\"_blank\">AngioDynamics misses by $0.02, misses on revenue</a> (April 2)</li></ul><div class=\"tiny-share-widget\" data-id=\"3447664\" data-linked=\"AngioDynamics down 7% on fiscal Q3 results\" data-tweet=\"$ANGO - AngioDynamics down 7% on fiscal Q3 results https://seekingalpha.com/news/3447664-angiodynamics-down-7-on-fiscal-q3-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3447664-angiodynamics-down-7-on-fiscal-q3-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:51 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447662\" data-ts=\"1554205740\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SGMO\" target=\"_blank\">SGMO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447662-sangamo-up-7-premarket-on-positive-hemophilia-gene-therapy-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sangamo up 7% premarket on positive hemophilia A gene therapy data</a></h4><ul><li>Sangamo Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SGMO' title='Sangamo Therapeutics, Inc.'>SGMO</a>) is up <font color=\"green\">7%</font> premarket on light volume in response to <a href=\"https://seekingalpha.com/pr/17462606-sangamo-pfizer-announce-phase-1-2-interim-data-investigational-hemophilia-gene-therapy\" target=\"_blank\">interim dat</a>a from a Phase 1/2 clinical trial evaluating its SB-525 gene therapy in patients with severe hemophilia A.</li><li>Eight patients have been treated across four dosage cohorts. They demonstrated dose-dependent increases in Factor VIII &#40;FVIII&#41; levels, including clinically relevant increases in FVIII activity in the higher dose cohorts. Patients receiving the highest dose (3e13 vg/kg) experienced normal FVIII levels.</li><li>Six weeks after infusion, the two patients receiving the highest dose of SB-525 achieved FVIII levels of 140% and 94% of normal, respectively, (as measured by a one-stage clotting assay) and 93% and 65%, respectively, as measured by a two-step chromogenic assay (considered to be a <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/25560793\" target=\"_blank\">higher standard</a> since the one-step assay can be influenced by nonspecific inhibition).</li><li>A dose-dependent reduction in the use of FVIII replacement therapy was also observed.</li><li>On the safety front, Orphan Drug- and Fast Track-tagged SB-525 was generally well-tolerated. One patient receiving the highest dose experienced a serious adverse event of hypotension and fever after infusion which resolved with treatment within 24 hours.</li><li>Longer term follow-up data will be submitted for presentation at a future medical conference</li><li>The company is collaborating with Pfizer (NYSE:<a href='https://seekingalpha.com/symbol/PFE' title='Pfizer Inc.'>PFE</a>) on development and commercialization.</li><li>Management will host a conference call at 8:00 am ET to discuss the results.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447662\" data-linked=\"Sangamo up 7% premarket on positive hemophilia A gene therapy data\" data-tweet=\"$SGMO $PFE - Sangamo up 7% premarket on positive hemophilia A gene therapy data https://seekingalpha.com/news/3447662-sangamo-up-7-premarket-on-positive-hemophilia-gene-therapy-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3447662-sangamo-up-7-premarket-on-positive-hemophilia-gene-therapy-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447653\" data-ts=\"1554205196\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WBA\" target=\"_blank\">WBA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447653-walgreens-boots-down-7-on-fiscal-q2-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Walgreens Boots down 7% on fiscal Q2 results</a></h4><ul><li>Walgreens Boots (<a href='https://seekingalpha.com/symbol/WBA' title='Walgreens Boots Alliance, Inc.'>WBA</a>) <a href=\"https://seekingalpha.com/pr/17462618-walgreens-boots-alliance-reports-fiscal-2019-second-quarter-results\" target=\"_blank\">Q2 results</a>: Revenues: $34,528M (+4.6%); Retail Pharmacy USA: $26,257M (+7.3%); Retail Pharmacy International: $3,082M (-7.1%); Pharmaceutical Wholesale: $5,738M (-0.3%).</li><li>Net Income: $1,156M (-14.3%); EPS: $1.24 (-8.8%); Non-GAAP EPS: $1.64 (-5.2%); Non-GAAP Net Income: $1,522M (-11.6%); Quick Assets: $818M (+4.2%); CF Ops: $1,195M (-62.7%).</li><li><strong>FY2019 Guidance</strong>: Non-GAAP EPS: growth expected to be roughly flat at constant currency rates from growth of 7% to 12%.</li><li>Shares are down <font color=\"red\">7%</font> premarket.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3447631-walgreens-boots-misses-0_08-misses-revenue\" target=\"_blank\">Walgreens Boots misses by $0.08, misses on revenue</a> (April 2)</li></ul><div class=\"tiny-share-widget\" data-id=\"3447653\" data-linked=\"Walgreens Boots down 7% on fiscal Q2 results\" data-tweet=\"$WBA - Walgreens Boots down 7% on fiscal Q2 results https://seekingalpha.com/news/3447653-walgreens-boots-down-7-on-fiscal-q2-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3447653-walgreens-boots-down-7-on-fiscal-q2-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>138&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447647\" data-ts=\"1554204516\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FVE\" target=\"_blank\">FVE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447647-five-star-senior-living-restructures-arrangements-senior-housing\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Five Star Senior Living restructures arrangements with Senior Housing</a></h4><ul><li>Five Star Senior Living (NASDAQ:<a href='https://seekingalpha.com/symbol/FVE' title='Five Star Senior Living Inc.'>FVE</a>)<a href=\"https://seekingalpha.com/pr/17462502-five-star-senior-living-announces-restructuring-business-arrangements-senior-housing\" target=\"_blank\"> agrees to restructure </a>its business arrangements with Senior Housing Properties Trust (NASDAQ:<a href='https://seekingalpha.com/symbol/SNH' title='Senior Housing Properties Trust'>SNH</a>) in a deal that will reduce its rent for communities it leases from Senior Housing and provide it with a $25M revolving credit line, while SNH shareholders will hold a majority stake in Five Star.</li><li>Starting Feb. 1, 2019, Five Star's aggregate monthly rent payments for the senior living communities it leases from SNH are reduced to $11.0M from $17.4M.</li><li>Five Star has sold ~$50M of property, plant, and equipment to SNH relating to the senior communities that it leases from SNH.</li><li>As of Jan. 1, 2020, the existing master leases as well as existing management agreements and pooling agreements  will be terminated and replaced with new management pacts for all 261 senior living communities owned by SNH and operated by Five Star.</li><li>With the conversion of the lease and management agreements, Five Star will issue common shares to SNH and SNH shareholders so that SNH will own a 34% stake in Five Star and SNH shareholders will hold a 51% stake.</li><li>SNH will reduce Five Star's debt or make a cash payment to Five Star in an amount equivalent to $75M.</li><li>The share issuances to SNH and SNH shareholders are subject to the approval by a majority of Five Star's stockholders.</li><li>SNH and ABP Trust, which together own ~44% of Five Star's outstanding common shares, have both agreed to vote in favor of the share issuances.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3440211-five-star-senior-living-q4-top-line-1-percent\" target=\"_blank\">Five Star Senior Living Q4 top line up 1%</a> (March 6)</li></ul><div class=\"tiny-share-widget\" data-id=\"3447647\" data-linked=\"Five Star Senior Living restructures arrangements with Senior Housing\" data-tweet=\"$FVE $SNH - Five Star Senior Living restructures arrangements with Senior Housing https://seekingalpha.com/news/3447647-five-star-senior-living-restructures-arrangements-senior-housing?source=tweet\" data-url=\"https://seekingalpha.com/news/3447647-five-star-senior-living-restructures-arrangements-senior-housing\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447646\" data-ts=\"1554204511\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADMA\" target=\"_blank\">ADMA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447646-fda-approves-adma-biologics-asceniv-shares-up-46-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA approves ADMA Biologics&#39; ASCENIV; shares up 46% premarket</a></h4><ul> <li>The FDA has <a href=\"https://seekingalpha.com/pr/17462337-fda-approves-asceniv-novel-intravenous-immune-globulin\" target=\"_blank\">approved</a> ADMA Biologics' (NASDAQ:<a href='https://seekingalpha.com/symbol/ADMA' title='ADMA Biologics, Inc.'>ADMA</a>) ASCENIV, Immune Globulin Intravenous, Human \u2013 slra 10% Liquid, formerly referred to as RI-002.</li><li>ASCENIV is used for the treatment of Primary Humoral Immunodeficiency Disease (\u201cPIDD\u201d or \u201cPI\u201d) in adults and adolescents (12 to 17 years of age). The commercial launch of product is anticipated during H2.</li><li>Shares are up <font color=\"green\">46%</font> premarket.</li>     </ul><div class=\"tiny-share-widget\" data-id=\"3447646\" data-linked=\"FDA approves ADMA Biologics&#39; ASCENIV; shares up 46% premarket\" data-tweet=\"$ADMA - FDA approves ADMA Biologics&#39; ASCENIV; shares up 46% premarket https://seekingalpha.com/news/3447646-fda-approves-adma-biologics-asceniv-shares-up-46-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3447646-fda-approves-adma-biologics-asceniv-shares-up-46-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447643\" data-ts=\"1554204264\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NIO\" target=\"_blank\">NIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447643-nio-updates-on-q1-deliveries\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NIO updates on Q1 deliveries</a></h4><ul><li>Nio (NYSE:<a href='https://seekingalpha.com/symbol/NIO' title='NIO Inc.'>NIO</a>) says aggregate deliveries of the ES8 model reached 15,337 vehicles on March 31, with 3,989 vehicles delivered in Q1.</li>    <li>The Chinese EV automaker says 1,805 ES8s were delivered in January, 811 in February and 1,373 in March.</li><li>Q1 ES8 deliveries exceeded the company\u2019s prior guidance range of 3.5K to 3.8K.</li><li>NIO  <font color=\"green\">+1.34%</font> premarket to  $5.28.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17462457-nio-inc-provides-first-quarter-2019-delivery-update\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3447643\" data-linked=\"NIO updates on Q1 deliveries\" data-tweet=\"$NIO - NIO updates on Q1 deliveries https://seekingalpha.com/news/3447643-nio-updates-on-q1-deliveries?source=tweet\" data-url=\"https://seekingalpha.com/news/3447643-nio-updates-on-q1-deliveries\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>53&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447642\" data-ts=\"1554204252\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/COMM\" target=\"_blank\">COMM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447642-commscopeplus-3_9-top-pick-from-new-bull\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CommScope +3.9% as top pick from new bull</a></h4><ul><li>Credit Suisse upgrades CommScope (NASDAQ:<a href='https://seekingalpha.com/symbol/COMM' title='CommScope Holding Company, Inc.'>COMM</a>) from Neutral to Outperform, names it as a top pick with \"highest conviction,\" and raises the target from the Street-low $20 to the Street-high $34.</li><li>The firm sees \"material\" upside from the Arris International acquisition with upside potential of more than 50% above current levels.</li><li>CommScope shares are <font color=\"green\">up 3.9%</font> pre-market to $23.10.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447642\" data-linked=\"CommScope +3.9% as top pick from new bull\" data-tweet=\"$COMM - CommScope +3.9% as top pick from new bull https://seekingalpha.com/news/3447642-commscopeplus-3_9-top-pick-from-new-bull?source=tweet\" data-url=\"https://seekingalpha.com/news/3447642-commscopeplus-3_9-top-pick-from-new-bull\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447638\" data-ts=\"1554203614\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QRVO\" target=\"_blank\">QRVO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447638-qorvo-gains-keybanc-leaves-sidelines\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Qorvo gains as KeyBanc leaves sidelines</a></h4><ul><li>KeyBanc upgrades Qorvo (NASDAQ:<a href='https://seekingalpha.com/symbol/QRVO' title='Qorvo, Inc.'>QRVO</a>) from Sector Weight to Overweight with the PT at $85, implying a 16% upside.</li><li>Last month, Goldman <a href=\"https://seekingalpha.com/news/3444747-goldman-boosts-qorvo-stabilizing-smartphones\" target=\"_blank\">raised</a> Qorvo's target on the \"compelling valuation\" and \"early signs of of smartphone unit stabilization.\"</li><li>Qorvo shares are <font color=\"green\">up 1.4%</font> pre-market to $74.25.</li><li>Update with details from the upgrade:</li><li>Analyst John Vinh cites increased confidence in market share gains after a trip to Asia.</li><li>Vinh says QRVO is well positioned to benefit from 5G and echos Goldman's belief that iPhone and Chinese smartphone demand are stabilizing.</li><li>The analyst sees \"favorable risk/reward\" given the Street's \"significant amount of skepticism\" in QRVO's ability to regain market share.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447638\" data-linked=\"Qorvo gains as KeyBanc leaves sidelines\" data-tweet=\"$QRVO - Qorvo gains as KeyBanc leaves sidelines https://seekingalpha.com/news/3447638-qorvo-gains-keybanc-leaves-sidelines?source=tweet\" data-url=\"https://seekingalpha.com/news/3447638-qorvo-gains-keybanc-leaves-sidelines\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447627\" data-ts=\"1554202639\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVS\" target=\"_blank\">NVS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447627-novartis-cosentyx-okd-in-china-for-psoriasis\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Novartis&#39; Cosentyx OK&#39;d in China for psoriasis</a></h4><ul><li>China's National Medical Products Administration has <a href=\"https://www.novartis.com/news/media-releases/novartis-first-class-cosentyx-approved-china-psoriasis-patients\" target=\"_blank\">approved</a> Novartis' (NYSE:<a href='https://seekingalpha.com/symbol/NVS' title='Novartis AG'>NVS</a>) Cosentyx (secukinumab), an interleukin-17A inhibitor, for the treatment of adult patients with moderate-to-severe plaque psoriasis.</li><li>Shares are down <font color=\"red\">1%</font> premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447627\" data-linked=\"Novartis&#39; Cosentyx OK&#39;d in China for psoriasis\" data-tweet=\"$NVS - Novartis&#39; Cosentyx OK&#39;d in China for psoriasis https://seekingalpha.com/news/3447627-novartis-cosentyx-okd-in-china-for-psoriasis?source=tweet\" data-url=\"https://seekingalpha.com/news/3447627-novartis-cosentyx-okd-in-china-for-psoriasis\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:57 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447626\" data-ts=\"1554202594\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WYNN\" target=\"_blank\">WYNN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447626-union-gaming-expects-win-for-wynn-in-massachusetts\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Union Gaming expects a win for Wynn in Massachusetts</a></h4><ul> <li>Union Gaming analyst John DeCree expects Wynn Resorts (NASDAQ:<a href='https://seekingalpha.com/symbol/WYNN' title='Wynn Resorts, Limited'>WYNN</a>) to maintain its Massachusetts license, but get hit with a substantial fine and be subjected to regulatory probation on top of additional oversight.</li> <li>\"Our view for a favorable outcome for Wynn Resorts is largely predicated on the company\u2019s swift and drastic response after the allegations against former Chairman &amp; CEO Steve Wynn were made public,\" writes Decree.</li> <li>Union Gaming lifts its price target on Wynn to $165.</li> <li>Shares of Wynn are <font color=\"red\">down 1.27%</font> in premarket trading to cut into their +30% YTD rally.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3447589-wynn-resorts-attempts-save-ma-gaming-license\" target=\"_blank\">Wynn Resorts attempts to save MA gaming license</a> (April 2)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3447626\" data-linked=\"Union Gaming expects a win for Wynn in Massachusetts\" data-tweet=\"$WYNN - Union Gaming expects a win for Wynn in Massachusetts https://seekingalpha.com/news/3447626-union-gaming-expects-win-for-wynn-in-massachusetts?source=tweet\" data-url=\"https://seekingalpha.com/news/3447626-union-gaming-expects-win-for-wynn-in-massachusetts\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447625\" data-ts=\"1554202044\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KAR\" target=\"_blank\">KAR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447625-kar-auction-services-lands-favorable-irs-ruling\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">KAR Auction Services lands favorable IRS ruling</a></h4><ul> <li>KAR Auction Services (NYSE:<a href='https://seekingalpha.com/symbol/KAR' title='KAR Auction Services, Inc.'>KAR</a>) announces that it received a favorable private letter ruling from the Internal Revenue Service with respect to the tax-free status of its previously announced spin-off of its Insurance Auto Auctions salvage auction business.</li> <li>CEO Jim Hallett calls the favorable tax ruling an important milestone towards completing the spin-off. \"We are pleased to continue moving forward with this transaction which will enhance the success of each business by creating two companies that will be leaders in their respective markets,\" says Hallett.</li><li>The separation still remains subject to a number of conditions.</li>  <li>KAR  <font color=\"green\">+1.11%</font> premarket to  $52.63.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17462056-kar-receives-favorable-irs-private-letter-ruling-tax-free-nature-previously-announced-salvage\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3447625\" data-linked=\"KAR Auction Services lands favorable IRS ruling\" data-tweet=\"$KAR - KAR Auction Services lands favorable IRS ruling https://seekingalpha.com/news/3447625-kar-auction-services-lands-favorable-irs-ruling?source=tweet\" data-url=\"https://seekingalpha.com/news/3447625-kar-auction-services-lands-favorable-irs-ruling\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}